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 Natural products have long been an important source of therapeutic compounds. The 
lanthipeptides, members of the ribosomally synthesized and post-translationally modified peptide 
class of natural products, have potential applications ranging from clinical imaging to cystic 
fibrosis treatment. Additionally, many lanthipeptides possess strong antimicrobial activity, 
making them particularly intriguing given the on-going antimicrobial resistance crisis. However, 
like most natural products, lanthipeptides generally require optimization to make them more 
suitable for therapeutic uses, and there is a pressing need to develop platforms and strategies that 
enable the exploitation of lanthipeptide activities for clinical applications. Three strategies were 
explored to achieve this goal. First, a yeast display platform was used to select a precursor to a 
lanthipeptide that binds its biosynthetic enzymes more tightly, potentially enabling further 
biochemical characterization of a key substrate-enzyme interaction required for lanthipeptide 
biosynthesis. Second, the antimicrobial lanthipeptide nisin was displayed on the surface of a 
M13 phage, and this display platform was used to select for a nisin variant that binds the small 
molecule target lipid II. Finally, the ability of the nisin-displaying phage to function as a broad 
host-range virion with potential applications in the genetic transformation of difficult-to-
transform bacteria or in a therapeutic setting was demonstrated. Together, these studies further 
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CHAPTER 1: INTRODUCTION 
1.1 Ribosomally synthesized and post-translationally modified peptides (RiPPs) 
For thousands of years, natural products have played a dominant role in treatment of 
human disease.1 Even in the modern era, where synthetic chemistry advances allow access to a 
virtually unlimited number of potential scaffolds and high-throughput screening enables the 
investigation of millions of drug candidates in a matter of days, natural products continue to play 
a central role in the development of therapeutic compounds.2 Natural products play a particularly 
prominent role in the development of antibacterial compounds.2,3 In fact, between 1981 and 
2014, only 26% of approved new chemical entities for treatment of bacterial infections were 
from a synthetic origin.2 With the advent of genome mining, where natural product-producing 
biosynthetic gene clusters can be identified through in silico methods, our appreciation for the 
diversity and breadth of natural products has grown. It is now clear that currently characterized 
natural products account for a tiny fraction of the overall secondary metabolite space, and many 
natural product scaffolds await discovery and characterization.4–6 However, the era of rapid and 
easy discovery of clinically valuable natural products has largely ended, a fact reflected in the 
decreased success rate of natural product-derived drugs in clinical trials over the last two decades 
compared to the five decades prior to that.2,7 This trend is particularly troubling for antibacterial 
compounds, where a dearth of new classes of antibiotics compounded by the rise of 
antimicrobial resistance makes the need for new chemical entities pressing.8,9 Exploitation of 
new natural product classes and development of new platforms for their discovery and 
optimization is vital to continue to leverage the diverse natural product supply for novel 
therapeutic compounds.  
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Ribosomally synthesized and post-translationally modified peptides (RiPPs) are one class 
of underutilized natural products that have the potential to treat fungal infections, bacterial 
infections, cystic fibrosis, neuropathic pain, and many other conditions.10,11 RiPP biosynthesis 
follows a simple logic (Figure 1.1).12  The primary sequence is genetically encoded, and 
transcription and translation of this gene yields the precursor peptide, consisting of a leader 
region and a core region. Modifying enzymes recognize and bind the leader region then install 
one or more post-translational modifications in the core region. Following modification, a 
protease removes the leader region of the peptide to yield the mature product.12 Despite this 
simple biosynthetic logic, RiPPs are an extraordinarily diverse family of natural products, with 
various members undergoing methylations, halogenations, macrocyclizations, epimerizations, 
and a host of other transformations.13 Moreover, given that the primary structure of these natural 
products is genetically encoded, mutations can be easily introduced into the core region of the 
peptide. Since the modifying enzymes rely on the leader peptide for substrate recognition, these 
mutant precursors are often processed into mature products.14 Hence, RiPPs are highly 
evolvable, exhibiting hypervariable core regions within naturally occurring classes of RiPPs12 
and making them excellent candidates for library creation and selection in the lab.14,15 
 
Figure 1.1. General RiPP biosynthetic logic. Note that the illustrated post-translational modifications are 




1.2 Lanthipeptides: a wide-ranging and well-studied RiPP family 
Lanthipeptides are one of the longest-studied RiPP families, with the lead member of the 
family, nisin, first described in 1928.16 During their biosynthesis, lanthipeptides undergo 
dehydration of select serine and threonine residues to yield dehydroalanine or dehydrobutyrine, 
respectively (Figure 1.2).12 The newly formed double bond in these dehydrated residues is 
conjugated to the carbonyl of the peptide backbone and thus is electrophilic. The next step in the 
biosynthesis is the formation of macrocycles through reaction of a dehydrated residue with a 
cysteine residue to yield a thioether linked macrocycle (Figure 1.2).17 These linkages are known 
as lanthionines when the dehydrated residue stems from a serine or as methyllanthionines when 
the dehydrated residue stems from a threonine. These thioether-linked macrocycles are the 
hallmark of the lanthipeptides. Formation of these rings is stereoselective, generally yielding the 
D configuration at the center originating from the dehydrated amino acid and maintaining the L 
configuration at the nucleophilic cysteine, although some LL configurations have been 
observed.18 Following installation of one or many dehydrated residues and (methyl)lanthionine 
rings, other post-translational modifications such as hydroxylation or halogenation can be 
mounted.13 In the last step, the leader peptide is cleaved by a protease and the now fully mature 
core peptide exported. 
In general, the introduction of the thioether linkages endows lanthipeptides with 
increased resistance to proteolysis and high thermal stability.19 Moreover, individual 
lanthipeptides have been discovered with remarkable additional properties. The lanthipeptide 
nisin is a potent antimicrobial agent with activity against a broad range of Gram positive 
bacteria. Intriguingly, despite more than 50 years of widespread use as a food preservative, very 




Figure 1.2. Post-translational modifications characteristic of lanthipeptides. Note that although the pictured 
dehydration mechanism uses glutamylated tRNAGlu to activate the hydroxyl group of a Ser or Thr for elimination 
this mechanism is not universally followed. Some classes of lanthipeptide use ATP to phosphorylate the hydroxyl 
prior to elimination.12 
 
lanthipeptides with a much more narrow range of activity. The producing organism, 
Ruminococcus flavefaciens, is found in the rumen of cattle, and it is possible that these peptides 
evolved to target a specific subset of bacteria found in this environment, thereby helping to 
maintain the balanced microbiota required by cattle.21 Duramycin, at 19 amino acids one of the 
smallest lanthipeptides, binds the phospholipid phosphatidylethanolamine but does not bind 
other, closely related phospholipids, and duramycin has potential as a clinical imaging agent for 
necrotic mammalian cells.22 It has also entered clinical trials as a therapy for cystic fibrosis.23 
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Other activities abound, and this wealth of potential applications makes lanthipeptides fantastic 
candidates for further study and development.11,19 
 
Figure 1.3. Three examples of lanthipeptides. Note that the dehydrated residues are colored blue, the thioether 
linkages in the macrocycles are colored red, and additional post-translational modifications are purple. Dha = 
dehydroalanine; Dhb = dehydrobutyrine. 
 
Despite their high potential value, clinical success with lanthipeptides has been elusive.11 
They are pharmacologically challenging, often displaying low solubility, low metabolic stability, 
and/or rapid clearance.11,24 Moreover, their large-scale production and formulation is also 
challenging,25 and to date none of the lanthipeptides that have entered clinical trials have 
proceeded to the market. Semisynthetic derivation of the mature products has been attempted but 
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with limited success, potentially due to the larger chemical landscape to explore in these peptides 
compared to small molecules.26 One possible solution to these issues is focusing on the discovery 
of massive numbers of new lanthipeptides that may in turn have better pharmacological 
properties. Genome mining studies have illustrated that there is a wealth of lanthipeptides present 
in sequenced bacterial genomes that have not been characterized, and many of these 
lanthipeptides likely contain novel post-translational modifications.10,27,28 This approach is being 
pursued in the van der Donk lab and many other labs, and it shows much promise. However, the 
sheer number of potential clusters to explore, many of which are not produced by the native 
producers in laboratory conditions, makes this a daunting task. Exploration of these clusters 
therefore requires heterologous expression or coexpression of the precursor peptide and the 
modifying enzymes, which can require months or years of optimization.29 Furthermore, once 
produced, the activity of the final product is unknown and is often difficult to discover. Without 
an established activity or isolation of the authentic material from the native producer, it is also 
difficult to determine whether the heterologous efforts have actually produced the true product.29  
A complementary approach is using the genetic malleability of lanthipeptides to create 
diverse libraries of compounds and then subjecting these libraries to a screen or selection to 
discover which variants possess the desired properties. Such an approach has the advantage that 
the selection or screen design can ensure that the products produced or discovered possess the 
desired activity and meet other design parameters. Iterative rounds of diversification and 
selection can be performed to further refine the output compounds, allowing for the artificial 
evolution of a lanthipeptide to yield exactly the desired product with the desired activity. 
However, this approach brings numerous challenges as well. First, making a high-quality library 
of compounds for a screen or selection requires an intimate understanding of how the modifying 
7 
 
enzymes engage and interact with their peptide substrates. Lacking such an understanding, one 
could create a library of diverse core peptides where the majority remain as linear peptides rather 
than modified peptides, thereby vastly decreasing the amount of true RiPP chemical space 
explored and risking selection of unmodified peptides that lack desirable qualities introduced by 
the modifications. Next, platforms for the screening or selection of the members of the library 
with the desired activity must be designed. This can be a complicated process requiring much 
trial and error, particularly given that there may be many qualities requiring optimization, such as 
solubility, stability, and target binding. Optimizing one of these variables would be quite 
challenging; optimizing two or more may require many rounds of selection for one trait followed 
by selection for the second desirable trait. Possibly due to these challenges, few platforms have 
been designed for a selection-based maturation of lanthipeptides, and hence I chose to focus on 
addressing this issue in my graduate work. 
 
1.3 Current lanthipeptide engineering platforms and dissertation work 
 Prior to the start of the work described here, two platforms for creation and selection of 
thioether-linked macrocyclic peptides had been described (Figure 1.4). The first published 
method described the display of nisin on the surface of a native producer, Lactococcus lactis. In 
this strategy, the precursor peptide was fused to an LPXTG motif, modified by the nisin 
modification enzymes, translocated across the cell membrane by the nisin translocation protein, 
and covalently bound to the outer peptidoglycan via sortase-mediated ligation using the LPXTG 
motif.30 A library was then constructed that randomized the three internal residues of a five-
residue peptide ring in a shortened nisin analog. This library was produced and displayed on the 
surface of L. lactis, then a selection was performed to identify variants that bound streptavidin. 
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One variant sequence, already known to be a streptavidin binder when cyclized via disulfide 
bonds rather than thioether linkages, was identified and its streptavidin-binding capability 
verified. The second existing selection methodology used in vitro translation of a leaderless, 
artificial precursor peptide coupled with chemical cyclization to yield a synthetic thioether-
linked peptide macrocycle fused to the encoding mRNA.31 This system was also employed in a 
test selection, creating a library randomizing the two internal residues of a four-member peptide 
ring and selecting for variants that inhibit Sortase A, a potential target for antimicrobial 
compounds. A number of variants were selected and their inhibitory ability verified. Another 
feature of the in vitro system is that it allows control of the stereochemistry at the cysteine 
residue in the (methyl)lanthionine rings, which can influence the stereochemistry at the other 
residue involved in making the ring. This in turn allows access to configurations that are not 
available enzymatically. 
 
Figure 1.4. Comparison of the natural lanthipeptide nisin and the libraries used for selection in two existing display 
methodologies for lanthipeptide-like peptide macrocycles. Note that the regions highlighted in gray are invariable 
regions, whereas the regions highlighted in red are the variable regions of the library peptides. Bold letters represent 
modified residues or residues participating in ring formation. Wild type nisin is provided as an example of a natural 
lanthipeptide. 
 
 While both above methods present many further opportunities for lanthipeptide 
discovery, they also have limitations. The bacterial display method is powerful, but most of the 
heterologous work performed with lanthipeptides and other RiPP systems has been performed in 
E. coli. Therefore, expansion of the system beyond RiPPs produced in L. lactis would first 
require optimizing the heterologous path. The display on the surface of bacteria also presents 
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other limitations to the types of selections that can be performed since any selection conditions 
that impede the integrity of the bacterium cannot be used. For the second system, the absolute 
stereochemical control at the cysteine residue is a powerful capability that is currently unrivalled 
in the enzymatic world, although our understanding of the substrate-enzyme interaction that 
defines stereochemistry is growing.32 However, with nonenzymatic installation of the thioether 
rings, there is no control over the ring topology, and any stereoselectivity is incidental. This 
greatly reduces the complexity that can be generated in a library, essentially limiting the library 
to contain only one macrocycle since the addition of multiple sites for cyclization would likely 
result in a mixture of products, and even this one macrocycle may be present as a mixture of 
stereoisomers. Most natural lanthipeptides like nisin, by comparison, are multi-ring structures, 
and the enzymatic processing of a lanthipeptide precursor installs a set ring pattern with 
extraordinary topological and stereochemical fidelity, without which the native function is lost.  
 I sought to develop strategies that, if successful, would expand the types of selection that 
can be performed and the complexity of lanthipeptide products that can be investigated. In the 
second chapter of this dissertation, I created a library of leader peptides displayed on yeast and 
selected members of this library that more tightly bound the modifying enzyme. This leader can 
now be used to further query the leader peptide-modifying enzyme interaction. Understanding 
this relationship is critical in understanding how these enzymes modify their substrates and 
install the ring topologies with such specificity. This understanding can aid in the design and 
quality of libraries for selections. In the third chapter, I describe the development and application 
of phage display of nisin. This system was designed using E. coli to manufacture the displayed 
peptides, and hence it should be rapidly expandable to other lanthipeptides and even other RiPPs 
whose biosyntheses have been reconstituted in E. coli. Additionally, the physical properties of 
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phage are radically different from those of L. lactis, and therefore selection conditions can be 
accessed with the phage that are unavailable to bacterial-displayed libraries. Finally, the fourth 
chapter describes an unexpected application of the nisin-displaying phage developed in chapter 
three. This phage was observed to be able to infect a broader range of host bacteria than the 
parent phage, and this surprising ability could have far-reaching impact on therapeutic phages 
and genetic manipulation of difficult-to-transform organisms. In sum, the studies reported here 
widen the reach of lanthipeptide selection strategies with the potential to bring these peptides 
with broad-ranging activities into the clinical realm.  
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CHAPTER 2: DISPLAY AND SELECTION OF A CYLLL VARIANT WITH 
INCREASED AFFINITY FOR THE MODIFYING ENZYME CYLM 
2.1 Introduction 
2.1.1 Significance of the leader peptide-modifying enzyme interaction  
 In 1988, Hansen and colleagues first reported the gene for nisin, confirming its ribosomal 
origin. Importantly, they also noted that the leader region of nisin is homologous to the leader 
region of subtilin, one of the few other confirmed ribosomally synthesized and post-
translationally modified peptides at that time, and they proposed that it is the conserved 
“character of the leader region that destines the precursor to be processed.”1 Interest in the role of 
the leader peptide has continued unabated. Mutational studies of nisin and related peptides 
revealed a conserved motif in class I lanthipeptide leader peptides required for modification and 
further revealed the role of the leader in modification and export.2–6 Moreover, the high substrate 
tolerance of lanthipeptide modification enzymes so long as the unmutated leader sequence is 
preserved has been demonstrated in both natural7,8 and artificial9–12 systems. This ability of the 
leader peptide to direct modification enzymes to act on a wide array of substrates makes 
lanthipeptides an excellent choice for combinatorial biosynthesis,13 and a deeper understanding 
of the leader peptide role enabling modification could make such efforts even more fruitful. 
Modification of lanthipeptides where the leader peptide was provided in trans,14,15 meaning 
separate from the core peptide, or covalently fused to the modifying enzymes16 has generated 
further intrigue in how the leader peptide influences the catalytic capability of the enzyme.   
 Understanding of the leader peptide-modifying enzyme interaction in class I lanthipeptide 
systems progressed significantly in recent years. In 2014, Ortega et al. reported a crystal 
structure of the nisin dehydratase NisB.17 Importantly, the precursor peptide NisA was bound in 
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the crystal, although the observed electron density was only sufficient to solve the structure of a 
portion of the nisin leader peptide bound to NisB. This study confirmed an important interaction 
between the leader peptide and the dehydratase. Report of the homologous MibB dehydratase 
crystal structure without a bound leader peptide allowed comparison of an apo and a holo class I 
lanthipeptide dehydratase and confirmed that leader peptide binding cooccurs with 
conformational shifts in the modifying enzyme.18 A follow up study leveraged the structural data 
from the NisB crystal structure to covalently link the nisin precursor peptide and NisB via an 
engineered disulfide bond, preventing translocation of the bound leader peptide during precursor 
dehydration. The bound precursor was fully dehydrated with a similar directionality as the 
unbound precursor, confirming that the leader peptide binds to a single site during 
modification.19 Finally, Burkhart et al. identified a shared structural motif present in NisB, the 
cyanobactin cyclodehydratase LynD, and the microcin C7-biosynthesis protein MccB.20 This 
motif, termed the RiPP recognition element (RRE), is homologous to the pyrroloquinoline 
quinone biosynthesis protein PqqD, another RiPP, and indeed appears to be a widespread peptide 
recognition motif in RiPP biosynthesis (Figure 2.1a,b).20  
 
Figure 2.1. The RRE recognition structure colored cyan with the leader peptide colored red in crystal structures of 
(a) LynD from PDB 4V1T and (b) NisB from PDB 4WD9. (c) The proposed leader peptide binding region from the 
crystal structure of CylM from PDB 5DZT. 
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 Understanding of the leader peptide-class II lanthipeptide synthetase interaction remains 
elusive. The class II synthetase is quite different from the class I dehydratase and cyclase. Class 
II lanthipeptides use a single enzyme termed a LanM to accomplish both dehydration and 
cyclization. The C-terminal domain of LanM enzymes is homologous to the cyclase enzyme 
from class I lanthipeptides. The N-terminal domain, which accomplishes the dehydration 
reaction, shows no homology to the class I dehydratases and even leverages a different 
mechanism entirely. No RRE motif has been bioinformatically identified in the class II 
synthetases. A crystal structure of the class II synthetase CylM was reported in 2015, revealing 
unexpected structural features, such as the high structural similarity of the dehydratase portion of 
CylM to eukaryotic lipid kinases. A cocrystal structure with the peptide substrate could not be 
acquired.21 A collection of antiparallel β-strands was identified in the structure and proposed to 
be the leader peptide binding site (Figure 2.1c), but experimental evidence corroborating this 
proposal has not yet been established. Moreover, the leader peptide itself lacks a conserved 
binding motif, and the mechanism that the leader peptide utilizes to enhance catalysis is 
unknown. Where the leader peptide of the CylM substrate peptides (termed the cytolysin 
precursor peptides) binds, whether such a motif is conserved in class II lanthipeptide synthetases, 
and even whether there is a single or multiple binding sites therefore remain unknown. 
 A yeast display system fusing the class II lanthipeptide lacticin 481 precursor to the Aga2 
yeast protein followed by binding of the associated synthetase has previously been developed.22 
In this system, the class II synthetase was fused to EGFP to allow selection via fluorescence 
activated cell sorting of a leader peptide with improved binding to its synthetase. Inspired by this 
effort, we chose to develop a similar system allowing selection of a leader peptide with improved 




23 CylM dehydrates select serine and threonine residues, forming 
dehydroalanine and dehydrobutyrine, respectively, through an ATP-dependent phosphorylation 
followed by elimination, and it then installs the thioether rings. It also subsequently installs the 
thioether linkages through a conjugate addition of the thiol of select cysteine residues onto the 
dehydrated residues. Given that a crystal structure of the enzyme has been acquired, we reasoned 
that if a peptide with improved binding to the enzyme could be selected, then application of the 
known crystallization techniques with addition of the selected tight-binding peptide could allow 
co-crystallization of the substrate-bound enzyme.  
 
2.2 Results 
2.2.1 Yeast surface display scheme 
Yeast surface display via creating a fusion of the gene encoding the Aga2 protein and the 
desired display protein is a well-established system.24 We formulated our system following 
design principles proposed by Wittrup and colleauges.25 The gene encoding either CylLL or 
CylLS was cloned into pCT302 to create a gene that, when expressed in yeast, yields the Aga2-
hemaglutinnin tag-linker-CylLL-c-Myc tag fusion (Figure 2.2a). This construct was made in E. 
coli, isolated, and used to transform Saccharomyces cerevisiae EBY100. To stain the yeast, the 
gene encoding CylM was cloned into pETDuet_Avi. This construct includes an AviTag marker 
at the C-terminus of the enzyme. When co-expressed with biotin ligase in media supplemented 
with biotin, the AviTag site will be biotinylated.26 Hence, the purified CylM_Avi construct will 
bind yeast expressing the Aga2-CylLL construct, and addition of a streptavidin-phycoerythrin 
conjugate will impart fluorescence to those cells with bound CylM (Figure 2.2b). Moreover, 
since the domain structure of CylM has been characterized both through crystallization and 
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biochemical analysis, we reasoned that we could use truncated forms of CylM for staining as 
well (Figure 2.2c). 
 
Figure 2.2. Summary of the yeast display platform. (a) Gene construct for the yeast display of CylLL. (b) Display 
and selection strategy. CylLL is fused on its N-terminus to the Aga2 protein, which binds with and is covalently 
linked via disulfide bridges to the Aga1 protein on the surface of yeast. CylM then binds the CylLL construct. CylM 
is biotinylated via an Avi tag on its C-terminus, through which a streptavidin-conjugated fluorophore is bound. (c) 
Crystal structure of CylM (PDB: 5DZT). The portion used for staining with the N-terminus only is tan. The portion 
used for staining with the C-terminus is green and includes the previously proposed leader peptide binding site in 
red. (d) The amino acid sequences of CylLL and CylLS.  
   
 We next sought to verify that expression of the gene constructs in yeast resulted in their 
display and that displayed peptides were bound by CylM. Following expression of both CylLL 
and CylLS in yeast, we first stained with an anti-c-Myc antibody followed with a secondary 
antibody conjugated to Alexa647 dye. Since the c-Myc tag is at the C-terminus of the displayed 
peptides, successful staining indicates that the full-length peptides are displayed. For both CylLL 
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and CylLS we observed a strongly fluorescent population, suggesting that this was the case 
(Figure 2.3a,b). Next, we stained with the biotinylated CylM_Avi construct followed by addition 
of streptavidin-phycoerythrin to determine whether CylM bound either substrate with sufficient 
affinity to allow sorting (Figure 2.3c,d). The average fluorescence of the population increased 
slightly with display of CylLS compared to an unexpressed control. However, comparison of a 
CylLL unexpressed control compared to expression revealed a distinct fluorescent population. 
The difference in affinities for CylLS versus CylLL is not likely due to different expression levels 
since c-Myc staining revealed similar levels of expression for both. It therefore is not clear why 
the two displayed peptides exhibit a differential binding interaction with CylM. It may be that the 
negatively charged c-Myc tag interferes with binding more with the shorter CylLS substrate than 
the longer CylLL substrate, or it could be that the enzyme has a genuinely higher affinity for 
CylLL. Regardless, the data suggested that CylLL would be a better choice of substrate moving 
forward. 
 As noted above, little is known about the binding site of CylLL and CylM, which 
provides both the dehydratase and cyclase activities. Therefore, it is possible that two binding 
sites exist, one each in the cyclase and dehydratase. Previous work from our lab demonstrated 
that the two domains remained functional when expressed as individual proteins.21,22,27 
Additionally, the proposed leader peptide binding portion is in the cyclase domain. Therefore, 
constructs encoding N-terminal CylM (the dehydratase portion termed Nterm_CylM, residues 1-
658) and C-terminal CylM (the cyclase portion termed Cterm_CylM, residues 658 and above) 
were constructed in pETDuet_Avi to allow for expression and purification of both individual 




Figure 2.3. Flow cytometry analysis of peptide and peptide-enzyme binding on yeast, showing that while both 
CylLS and CylLL are displayed, only CylLL has a robust interaction with CylM-Avi. (a) Analysis of the expression 
of CylLS (grey) compared to an unexpressing control (red) via staining with a c-Myc antibody and a secondary 
antibody conjugated to Alexa647 dye. (b) Analysis of the expression of CylLL (grey) compared to an unexpressing 
control (red) via staining with a c-Myc antibody and a secondary antibody conjugated to Alexa 647 dye. (c) CylLS-
displaying yeast stained with CylM-Avi/streptavidin-phycoerythrin (grey) compared to an unexpressed control (red). 
(d) CylLL-displaying yeast stained with CylM_avi/streptavidin-phycoerythrin (grey) versus an unexpressed control 
(red).  
 
domains of CylM compared to the full-length CylM was then compared using the same flow 
cytometry methodology and equivalent molar concentrations (20 M) (Figure 2.4). The full-
length CylM and the Nterm_CylM clearly bound the displayed CylLL construct. The 




Figure 2.4. Comparison of CylLL-displaying yeast stained with various CylM-Avi contructs. (a) Unstained control 
population. (b) Population stained with full-length CylM (grey) against the control population (red). (c) Population 
stained with C-terminal CylM (grey) against the control population (red). (d) Population stained with N-terminal 
CylM (grey) against the control population (red).  
 
2.2.2 CylLL library creation 
 To select for a leader peptide with improved affinity for CylM, we created a library of 
CylLL variants using wild type CylLL leader peptide as a template for error-prone polymerase 
chain reaction (EP-PCR). Library 1 was created using 30 rounds of EP-PCR following an 
established protocol,28 and the insert attained by EP-PCR was assembled in yeast via 
transformation-assisted recombination (Figure 2.5a).  Sequencing of this library suggested the 
mutation rate was 0.4 amino acid mutations per assembled leader sequence (Figure 2.5b). This 
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library was then used as a template for a further 30 rounds of EP-PCR, yielding library 2 with a 
mutation rate of 1.3 mutations per leader sequence. (Figure 2.5b). Both libraries also presented 
frameshift-mutated cores: 1/10 of sequenced cores in the first library and 4/8 sequenced cores in 
the second library were thus no longer homologous to the CylLL core (Figure 2.5b). This high 
degree of mutation in the core sequence was unanticipated, although it may be due to the high 
number of repeated codons flanking the leader sequence. Assuming that each assembled 
sequence was an unique variant, serial dilution followed by plating on selective media suggested 
that library 1 consisted of 3.0 × 105 variants and library 2 consisted of 5.2 × 104 variants. Equal 
amounts of both libraries were combined to create the final library of approximately 3.5 × 105 
variants, although given the mutation rate in library 1 the actual number of variants was likely 









Figure 2.5. Library creation and sequencing. (a) Library creation strategy. Total library members are approximately 
3.5 × 105. (b) Results from Sanger sequencing of library members. Point mutations are bolded and red. Scrambled 
sequences due to a point deletion are italicized, underlined, and blue.  
Wt       SASENLSVVPSFEELSVEEMEAIQGSGDVQAE   TTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHCEQKLISEEDL 
>1.1     SASENLSVVPSFEELSVEEMEAIQGSGDVQAE   TTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHCEQKLISEEDL 
>1.2     SASENLSVVPSLEELSVEEMEAIQGSGDVQAE   TTPVLQLQQPQQQAAQHVVGLVVVFLPVLPLLLA 
>1.3     SASENLSVVPGFEELNVEEMEAIQGSGDVQAE   TTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHCEQKLISEEDL 
>1.4     SASENLSVVPSFEELSVEEMEAIQGSGDVQAE   TTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHCEQKLISEEDL 
>1.5     SASENLSVVPSFEELSVEEMEAIQGSGDVQAE   TTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHCEQKLISEEDL 
>1.6     SASENLSVVPSFEELSVEEMEAIQGSGDVQVE   TTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHCEQKLISEEDL 
>1.7     SASENLSVVPSFEELSVEEMEAIQGSGDIQAE   TTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHCEQKLISEEDL 
>1.8     SASENLSVVPSFEELSVEEMEAIQGSGDVQAE   TTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHCEQKLISEEDL 
>1.9     SASENLSVVPSFEELSVEEMEAIQGSGDVQAE   TTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHCEQKLISEEDL 
>1.10    SASENLSVVPSYEELSVEEMEAIQGSGDVQAE   TTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHCEQKLISEEDL 
>2.1     SASENLSVVPSFGELSVEELEAIQGSGDVQAE   TTPVCAVAATASARPHRFVQLQHRSSKQRSMWLGWWWYFYRCYRCC 
>2.2     SASENLSVVPSFEELSVEEMEAIQGSGDVQAE   TTPVCAVAETAAARPHRFVQLQQPQQQAAQHVVGLVVVFLPVLPLLLA 
>2.3     SASENLSVVPSFEELSVGEMEAILVAVMFSQKPHRFVQLQQPQRQDHTGLCSCSNRSSKQRSMWLGWWWYFYRCYRCC 
>2.4     SASENLSVAPSFEELSVEEKEAIQGSGDVQAE   TTPVCAVAATAAAKPHRFVQLQQPQQQAAQHVVGLVVVFLPVLPLLLA 
>2.5     SASENLSVVPSFEDLSVEEMGAIQGSGDVQAE   TTPVCAVAATAAARPHRFVQ* 
>2.6     SASENLSVVPSFEELSVEEMEAIQGSGDVQAG   TTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHCEQKLISEEDL 
>2.7     SASENLSVVPSFEERSVEEMEAIQGSGDVQAE   TTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHCEQKLISEEDL 
>2.8     SASENLRVVPSYEELSVEEMEAIQGSGDVQAE   TTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHCEQKLISEEDL 
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2.2.3 Selection rounds 
Given the weak affinity of the C-terminal portion of CylM for CylLL, we chose to stain 
the library with the N-terminal and full-length CylM portions only. The library was amplified 
and expressed, then divided into three equal aliquots and incubated with 20 M N-terminal 
CylM, 20 M full-length CylM, or no enzyme. After incubation with the enzyme, the cells were 
 
Figure 2.6. Analysis of populations subject to the first round of FACS. In each figure, P2 is the gate used to select 
the top 1% of variants, and these individual points are green. Red points represent events that are roughly within the 
range of the negative control. Blue events are more fluorescent than the negative control.  (a) Analysis of the 
negative control population. (b) Analysis of the N-terminal CylM-stained population (left) and results of the sorted 




washed then incubated with the streptavidin-phycoerythrin conjugate to complete the staining 
process. After staining, the preparations were sorted sorted via fluorescence-activated cell sorting 
(FACS). The unstained negative control was first assessed via flow cytometry to serve as a 
baseline fluorescence value (Figure 2.6a). The stained cultures were then analyzed with the same 
parameters and gated to select the 1% of the population with the highest fluorescence (Figure 
2.6b,c). The entire culture was then sorted, consisting of between 1.5 × 105 and 3.5 × 105 cells. 
The sorted fractions were amplified and then a portion was spread on selective solid 
media. Individual yeast colonies were selected from solid media, grown in liquid cultures, and 
the plasmid isolated. The isolated plasmid was used to transform E. coli in order to isolate 
sufficient plasmid for sequencing, re-isolated, and finally sequenced. Five sequences were 
determined for each sorted library (Figure 2.7). Full length CylM showed a distinctly different 
sequence preference compared to N-terminal CylM. All five colonies sequenced from full length 
CylM showed an intact core region, whereas none of the five sequences from the N-terminal 
CylM-sorted colonies showed an intact core. Given that the full-length CylM contains both the 
N-terminal dehydratase domain and the C-terminal cyclase domain, it strongly suggests that the 
cyclase domain has some affinity or recognition of the core, and this possibility is explored more 
in the discussion below.  
 
Figure 2.7. Outcome of first sort based on five sequences determined from each population. The leader region is 
marked with light blue, and point mutations are bolded and italicized. The core region is not highlighted, and 




 Having observed the markedly different preferences of the full- versus the N-terminal- 
CylM stain, a second round of sorting was undertaken. The library sorted with the full-length 
CyM was stained with 10 M N-terminal CylM and sorted again. The library sorted with the N-
terminal CylM was also stained with 10 M N-terminal CylM and sorted. Again, plasmid was 
extracted from individuals in both libraries and five clones were sequenced from each library 
(Figure 2.8). We anticipated that the library sorted first with the full-length CylM would have 
more variants containing an intact core region; hence, if the N-terminal portion had affinity for 
the core it would likely return more intact core regions. In the instance where the N-terminal 
CylM sorted library was sorted a second time with N-terminal CylM, we expected to see once 
again scrambled core but largely intact leader region. Of the ten clones sequenced from the two 
libraries, only one had an intact core. While the same caveats as noted above still apply, I 
interpret this to confirm that the N-terminal region of CylM has a strong affinity for the leader 













Since our results with the first two rounds of sorting were convincing that an unidentified 
leader peptide binding motif exists in the N-terminal region of CylM, we chose to continue 
staining and sorting the library with the N-terminal region only. Three additional rounds of 
Wt       SASENLSVVPSFEELSVEEMEAIQGSGDVQAE   TTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHCEQKLISEEDL 
>FN1     SASENLSVVPSFEELSVEEMEAIQGSGDVQAE   TTPVCAVAANRSSKQRSMWLGWWWYFYRCYRCC 
>FN2     SASENLSVVPSFEELSVEEMEAIQGSGDVLAD   TTPVCAVAAPQQQDHTGLCSCSNRSSKQRSMWLGWWWYFYRCYRCC 
>FN3     SASENLSVVPSFEELSVEEMEAIQGSGNVQAE   TTPVCAVAATQQQDHTGLCSCSNRSSKQRSMWLGWWWYFYRCYRCC 
>FN4     SASENLSVVPSFEGLSVEEMEAIQGSGDVQAE   TTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHCEQKLISEEDL 
>FN5     SASENLSVVPSFEELSVEEMEAIQGSGDVQAE   TTPVCAVAATAASRPHRFVQLQQPQRQNHTGLCSCSNRSSKQRSMWLGWWWYFYRCYRCC 
>NN1     SASENLSVVPSFEELSVEEMEAIQGSGDVQAE   TTPVCAVAAPQQQDHTGLCSCSNRSSKQRSMWLGWWWYFYRCYRCC 
>NN2     SASENLSVVPSFEELSVEEMEAIQGSGDVQAE   TTPVCAVAAPQQQDHTGLCSCSNRSSKQRSMWLGWWWYFYRCYRCC 
>NN3     SASENLSGVPSFEELGVEEMEAIQGSGDVQAE   TTPVCAVAATTAAATQSQQQDHTGLCSCSNRSSKQRSMWLGWWWYFYRCYRCC 
>NN4     SASENLSVVPSFEELSVEEMEAIQGSGDVQAE   TTPVCAVAATASSKQRSMWLGWWWYFYRCYRCC 
>NN5     SASENLSVVPSFEELSVEEMEAIQGSGNVQAE   TTPVCAVAATQQQDHTGLCSCSNRSSKQRSMWLGWWWYFYRCYRCC 
Figure 2.8. Outcome of the second round of sorting. “FN” indicates a result where the first selection was performed 
after staining with the full-length CylM and the second round of sorting was performed after staining with the N-
terminal portion of CylM. “NN” indicates a result where both rounds of sorting were performed after staining with 
the N-terminal portion of CylM. 
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sorting were performed as above, with the exception that only 2.5 M N-terminal CylM was 
used to stain for the final sort. Six clones were sequenced from the final sorted library. A Q-to-L 
consensus mutation was observed at the position in the leader peptide that is 9 residues prior to 
the start of the core peptide, denoted position -9. Given the emergence of a consensus mutation 
as well as the strong fluorescent response of the binding population (Figure 2.9), further sorts 










2.3 Discussion and outlook 
Our results demonstrate a marked difference in binding of CylLL between the N-terminal 
dehydratase domain and the full length CylM. The results in Figure 2.4 comparing the binding of 
Cterm_CylM, full-length CylM, and Nterm_CylM to the wild type CylLL peptide suggest that 
the cyclase domain does not have as strong an affinity for the CylLL peptide as the N-terminal 
dehydratase domain, even though the cyclase domain contains the proposed β-sheet leader 
peptide binding domain. Although it is possible that the proposed leader peptide binding site may 







Figure 2.9. Outcome of five consecutive rounds of sorting using the Nterm_CylM stain. (a) The leader peptide 
region from five sequences of the final sorted library. Point mutations are colored in red. (b) Histogram 
illustrating the control (red) and stained populations (grey) in the final sort. Note that the sort was performed by 




is at least not the only site where the leader peptide binds and may not in fact bind the leader 
peptide at all. As noted before, the c-Myc tag at the C-terminus of the displayed peptide is 
negatively charged, and this may interfere with binding of a protein that has some affinity for the 
core peptide of CylLL; however, the weaker affinity of the cyclase domain for the precursor 
peptide is consistent with the observation from class I modifying enzymes that a cyclase NisC, 
homologous to the cyclase domain of LanM enzymes, binds the peptide substrate more weakly 
than the associated dehydratase NisB.3 
  Despite the small number of sequenced colonies, the selection also supports the idea that 
the N-terminal dehydratase domain and the full length CylM are markedly different in which 
sequences of substrate they bind. Comparison of the sorting results from the first and second 
round of selection suggests that the N-terminal dehydratase derives its affinity for the peptide 
substrate from the leader peptide alone, whereas the full length CylM has affinity for the leader 
peptide and the core peptide. It is reasonable that the cyclase domain imparts affinity for the core 
peptide due to the specific nature of the reactions it catalyzes. Not taking into consideration 
stereochemistry, there are 210 possible rings that could be formed through cyclase-catalyzed 
conjugate addition of a thiol onto a dehydroamino acid in CylLL (7 dehydrated residues and 3 
cysteine residues). However, the cyclase domain accomplishes the formation of exactly 3 rings. 
Although many questions remain about how this domain achieves this exquisite selectivity, a 
stronger interaction between the cyclase and the core peptide is likely required than between the 
dehydratase domain and the core. It should be noted, though, that the highly charged c-Myc tag 
at the C-terminus of the core peptide could bias the N-terminal portion against selection of the 
full-length peptide. Additionally, although ATP was not present in the sorting mixture, it is 
possible that the N-terminal portion of CylM contains a bound ATP and effects a single 
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dehydration in intact cores, thereby biasing the cyclase portion to bind to intact cores with a 
dehydrated residue since they more closely resemble the native substrate of the enzyme. 
The result above is also consistent with previous reports, which used chimeric leader-core 
peptide constructs to further suggest that LanMs have affinity for both the core and the leader 
peptides.29 Additionally, the class I cyclase NisC, which is homologous to the cyclase domain of 
CylM, reportedly has a higher affinity for the intact precursor peptide than the leader peptide 
alone.30 The consistency of the selection results with these orthogonal data suggest that the yeast 
display scheme queries the interaction between CylM and CylLL in a relevant fashion, and that 
the fusions introduced at the termini of the displayed peptide and at the C-terminus of the 
enzymes do not perturb the CylLL-CylM interaction sufficiently to make conclusions irrelevant. 
After five rounds of selection a population of yeast cells expressing CylLL variants with 
significantly enhanced fluorescence was identified. A small number of clones were sequenced, 
and it is possible that other variants not reported here were also significantly enriched. However, 
it is striking that half of the sequenced population contains the same Q-9L mutation, and it 
suggests that this mutant indeed may bind CylM more strongly than the wild-type leader peptide. 
Further tests with this peptide, such as fluorescence polarization or CylM activity, could 
elucidate the impact of this mutation, although preliminary work by I. Rahman in the van der 
Donk lab suggests that fluorescence polarization is a not a suitable technique for investigating 
the substrate-CylM interaction. It was also noted that the Q-9L mutation greatly impacts the 
grand average of hydropathicity (GRAVY) of the leader peptide, determined using the Expasy 
tool (https://web.expasy.org/protparam/). The GRAVY increased from -0.209 in the wild type to 
0.019 in Q-9L. In fact, all the mutations identified in the leader domain after five rounds of 
sorting increase the GRAVY score (Figure 2.10). The hydropathicity of a protein is a numerical 
30 
 
estimate of where it lies on a spectrum from hydrophilic to hydrophobic, where a more positive 
value represents a greater degree of hydrophobicity.31 A plot of the average GRAVY score 
against the round of evolution suggests that that the GRAVY score generally increases with each 
round. The trend is strong despite the small number of sequences (R2 = 0.82). The data therefore 
suggests that our selection may enhance binding nonspecifically by enhancing the propensity of 
the leader peptide to bury itself in the more hydrophobic enzyme rather than remain solvent 
exposed. It is possible that such an impact still results in a leader peptide that is more likely to 
remain bound to the enzyme during crystallization, but it also may favor a non-specific or non-
physiological binding site.  
 
Figure 2.10. Plot of the GRAVY score versus the round of selection. Average for each round of selection are plotted 
as black asterisks. Individual results are grey dots. The best-fit line equation and r-squared statistic are displayed. 
Note that selection round 0 represents the GRAVY data for the library. 
  
Intriguingly, the mutations identified in this selection did not change the charge of the 
leader peptide, whereas most mutations identified in the similar selection using the lacticin 481 
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system increased the negative charge of the leader peptide.22 Comparison of the two leader 
peptides reveal that both contain a stretch of negatively charged residues in the leader peptides, 
and in fact this is typical of all class II lanthipeptide leader peptides.32 It is possible that this 
negatively charged stretch is a hallmark characteristic of class II lanthipeptide synthetase 
substrates.16 This acidic stretch of amino acids is preserved largely intact throughout the 
selection. In the unselected library, 57% of the observed mutations (8/14) occurred within the 
acidic stretch, whereas in the final library only 25% of the observed mutations occurred in this 
stretch, and none of the rounds of selection had more than 30% of the observed mutations 
occurring in this stretch (Figure 2.11). To test the significance of this observation, the data was 
pooled into “selected” and “unselected” categories and then the number of mutations within the 
conserved, charged region was compared to the number of mutations outside of the conserved 
region. Fisher’s exact test was chosen as the most appropriate for such a comparison,33 and the 
null hypothesis is that the probability of mutations occurring in the acidic, charged stretch of the 
leader peptide is as likely in the sequenced members of the unselected library as in the sequenced 
members of the library after any selection. The statistic was calculated to be p = 0.02, suggesting 
that the null hypothesis should be rejected. The frequency of mutations in the conserved, charged 
region prior to selection is thus not equivalent to the frequency of mutations in the charged 




Figure 2.11. Analysis of mutation frequency in sequences from the unselected library versus one or more rounds of 
selection. The charged region of the leader peptide is depicted as the red column, the other regions are depicted as 
the blue columns, and point mutations are depicted as black rectangles. The clear visual trend – fewer mutations in 
the charged stretch following any degree of selection for binding to the modifying enzyme – is supported by a 
Fisher’s exact test as described in the text.  
 
This conclusion suggests that most mutations in the acidic stretch are deleterious for 
binding, and therefore following selection mutations tend to accumulate in regions that are 
unimportant for binding. Therefore, if we inverted the system and displayed a library of CylM 
where each variant contains 2-4 mutations, then expressed the precursor CylLL fused to the Avi 
tag and linked via biotin to streptavidin-phycoerythrin, we could perform one or more rounds of 
selection for CylM. High throughput sequencing of the selected CylM mutants would reveal 
regions with few mutations and regions that are frequently mutated. Regions of low mutation 
would be vital either for protein folding or for leader peptide binding. Such “hits” could be 
confirmed through heterologous expression of targeted alanine mutants followed by circular 
dichroism spectroscopy to verify appropriate folding and fluorescence polarization to assess 
leader peptide binding. Such an approach could prove particularly useful in this case where the 
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interaction between leader peptide and modifying enzyme may be due to a charge-charge 
interaction across a broad enzyme-peptide interface rather than a series of more specific residue-
residue interactions.  
Ultimately, further work as recommended above or through other methods is required to 
determine where the leader peptide binds CylM. Nonetheless, the studies detailed here 
demonstrate that the previously proposed binding region is at minimum not the only binding 
region, if indeed it binds the leader peptide at all. Moreover, the display methodology used here 
could be expanded to further explore regions necessary for protein-peptide interaction, and it 
may be applicable to other systems as well. Finally, the observation that the selection yielded an 
increasingly hydrophobic leader peptide suggests that one means to generate a leader peptide 
which binds more tightly to the enzyme is to simply increase its hydrophobicity. If indeed this 
leader peptide can be co-crystallized with the enzyme, this could serve as a general strategy for 
creating leader peptides that remain bound to the modifying enzymes upon crystallization.   
 
2.4 Materials and methods 
Commercial materials. All chemicals were purchased from ThermoFisher Scientific 
(Pittsburgh, PA) unless otherwise noted. Luria-Bertani (LB) and Terrific Broth (TB) were 
purchased from Fisher Scientific. Restriction enzymes and Phusion DNA polymerase were 
purchased from New England Biolabs (Ipswich, MA). Plasmid mini-prep kits were purchased 
from Qiagen (Valencia, CA). Yeast plasmid miniprep kit was purchased from Zymo Research 
(Irvine, CA). Amicon centrifugal concentrators were purchased from Millipore (Billerica, MA). 
DNA oligonucleotides and synthetic DNA gene fragments (gBlocks) were purchased from 
Integrated DNA Technologies (Coralville, IA). Anti-c-Myc chicken antibody (cat. no. A-21281) 
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and Alexa647 goat anti-chicken secondary antibody (cat. no. A-21445) was purchased from 
Molecular Probes (Eugene, OR). Streptavidin-phycoerythrin stock (cat. no. S-866) was 
purchased from Thermo-Fisher (Pittsburgh, PA) at 1 mg/mL stock concentration.  
 
Strains. Saccharomyces cerevisiae EBY100 was used for yeast display. Escherichia coli 
DH10B-T1R was used for cloning. E. coli BL21(DE3) was used for protein expression.  
 
Plasmid construction. The gene encoding CylLL was cloned out of pET15b-CylLL using 
primers CylL_L_NheI_FP and CylL_L_cmyc_XhoI_RP (Table 2.1). It was digested with NheI 
and XhoI then ligated into pCT302 cut with NheI and XhoI using NEB T4 ligase as per the 
manufacturer’s protocol to yield pCT302-CylLL. The gene encoding CylLS was likewise cloned 
out of pET15b-CylLS using primers CylL_S_NheI_FP and CylL_S_cmyc_XhoI_RP. It was 
digested with NheI and XhoI then ligated into pCT302 cut with NheI and XhoI using NEB T4 
ligase as per the manufacturer’s protocol to yield pCT302-CylLS (notebook references 
17Feb2014, 18Feb2014, 23Feb2014, 24Feb2014).  
 
The gene encoding CylM was cloned out of pRSF-CylM using primers FP_CylM_pDuet and 
RP_CylM_pDuet then assembled into pETDuet-Avi cut with NotI/BamHI using Gibson 
isothermal assembly. The N-terminal portion of CylM was cloned out of pRSF-CylM using 
primers FP_CylM_pDuet and CylM_Nterm_RP then assembled in the same way into pETDuet-
Avi. The C-terminal portion of CylM was cloned out of pRSF-CylM using primers 
CylM_CTerm_FP and RP_CylM_pDuet then assembled in the same way into pETDuet-Avi 
(notebook references 30May2014, 06Jun2014, 09Jun2014, 07Jul2014, 08Jul2014). 
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A variant of pCT302-CylLL was constructed that replaced the leader peptide region of the gene 
encoding CylLL with an NheI cut site to allow linearization of the vector. Once digested with 
NheI, this plasmid will yield ends that overlap with the EP-PCR construct, allowing 
recombination in yeast. Using pCT302-CylLL as a template, the CylLL core and backbone 
regions of the leader were amplified with the primers CylLCore_FP and CylLCore_RP. The 
product of this PCR reaction was subjected to Gibson isothermal assembly to yield pCT302-
NheI (12Jan2015, 14Jan2015, 16Jan2015, 19Jan2015). 
The plasmid pETDuet-Avi was constructed by Dr. Mark Walker. The vector pETDuet was 
digested with NcoI and KpnI as per the manufacturer’s directions. The synthetic gene block 
pETDuet-His-Avi-Tag (Table 2.3), encoding a decahistidine tag followed by a series of 
restriction sites including NotI and BamHI and finally the Avi tag, was assembled with the cut 
backbone using an isothermal assembly reaction to yield pETDuet-Avi. 
The plasmid pColA-BirA was constructed by Dr. Mark Walker. The tac promoter was amplified 
using primers Ptac F1 and Ptac R1. The BirA gene was amplified using primers BirA F1 and 
BirA R1. The pCOLA backbone was amplified using primers pCOLA F1 and pCOLA R1. The 
three amplicons were combined in an isothermal assembly reaction to yield pColA-BirA. 
Expression and purification of enzymes. E. coli BL21(DE3) cells were transformed with 
pCola-BirA and the appropriate pETDuet-Avi construct (CylM, CtermCylM, or NtermCylM). 
An overnight culture of the freshly transformed cells in Terrific Broth (TB) was used to inoculate 
at 1% v/v a 2 L flask of TB with 25 g/mL kanamycin, 50 g/mL ampicillin, and 50 M biotin. 
The culture was grown with shaking at 37 C until the OD600 was between 0.6 to 0.8, then the 
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culture was cooled on ice for 20 min. IPTG was then added to 0.2 mM to induce and the culture 
was returned to the shaker at 16 C and expression continued with shaking for 18-20 h. The cells 
were then harvested at 9110 ×g for 10 min, then frozen at -80 C until purification (notebook 
reference 25Jul2014). 
All purification steps were conducted on ice or in the cold (4 C) room. Cells were resuspended 
in ice-cold start buffer (20 mM HEPES, pH 7.5, with 1 M NaCl) at 5 mL/g. Cells were lysed 
using the Avestin homogenizer then loaded onto 5 mL of Clontech Ni-IDA resin pre-equilibrated 
with start buffer. After loading, the resin was washed with 50 mL of start buffer then 50 mL of  
start buffer + 50 mM imidazole. The protein was eluted in 20 mL of start buffer + 500 mM 
imidazole. The eluted protein was concentrated using an Amicon 30 kDa MW cutoff filter and 
desalted using a GE healthcare PD10 desalting column according to the manufacturer’s 
instructions. The resulting eluent was again concentrated using an Amicon 30 kDa MW cutoff 
filter and the concentration was determined using the extinction coefficient calculated from 
Expasy (https://web.expasy.org/protparam/). The purified product was then divided in 10 L 
aliquots, flash-frozen, and stored at -80 C (notebook reference 13Aug2014). 
Expression of Aga2-CylLL and Aga2-CylLS in S. cerevisiae. The construct pCT302-CylLL or 
pCT302-CylLS was used to transform S. cerevisiae using a transformation protocol from the 
literature.34 A master mix was prepared containing 20 L of 2 M lithium acetate, 80 L of 50 
%w/v PEG3350, and 0.8 L of β-mercaptoethanol. An aliquot of 2 mg/mL salmon sperm was 
boiled at 100 C for 5 min, then 15 L was added to the above mixture. To this, 15 L of the 
pCT302-CylLL at 181 ng/L was added, then one large colony of S. cerevisiae was added to the 
mixture. The entire mixture was incubated with shaking at 30 C for 30 min then pelleted by 
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centrifugation at 845 ×g. The supernatant was discarded. The pellet was resuspended in 50 L of 
water and spread on SD-CAA agar (5.4 g Na2HPO4, 8.56 g NaH2PO4*H2O, 182 g sorbitol, 15 g 
agar, 20 g dextrose, 6.7 g Difco yeast nitrogen base, 5 g casamino acids, 1 L water, autoclaved). 
The plate was placed at 30 C for 48 h (notebook reference 03Mar2014, 06Mar2014).  
A single colony from each plate was inoculated into 100 mL of SD-CAA media (5.4 g Na2HPO4, 
8.56 g NaH2PO4*H2O, 182 g sorbitol, 20 g dextrose, 6.7 g Difco yeast nitrogen base, 5 g 
casamino acids, 1 L water, sterile filtered) and grown with shaking at 30 C for 48 h. Cultures 
were then spun down at 2400 ×g for 3 min. The resulting pellet was resuspended in ~10 mL of 
SG-CAA media (5.4 g Na2HPO4, 8.56 g NaH2PO4*H2O, 182 g sorbitol, 20 g galactose, 6.7 g 
Difco yeast nitrogen base, 5 g casamino acids, 1 L water, sterile filtered), then spun down at 
2400 ×g for 3 min. The resulting pellet was again resuspended in 100 mL of SG-CAA to induce 
expression and transferred to a fresh flask, then grown at 20 C for 48 h to express and display 
the peptides on the surface (notebook references 16Oct2014, 18Oct2014). 
 
Creation, transformation, and expression of the CylLL library. EP-PCR was used to create 
the a library of cylLL based on a previously reported protocol.
28 Using pET15b-CylLL as template 
to amplify the leader peptide region only, a 100 L reaction was prepared containing 42.5 μL of 
water, 10 μLof Taq standard 10x buffer, 11 μL of 50 mM MgCl2, 4 μL of dNTP mix (25 mM 
dCTP, 25 mM dTTP, 5 mM dATP, 5 mM dGTP), 10 μL of primer mix (10 μM each forward and 
reverse primer), 10 μL of template at 50-100 ng/μL, and 2 μL of 25 mM MnCl2. The mixture 




Next, 1 μL of Taq DNA polymerase (5 U/μL) was added to the mixture. The mixture was 
returned to the thermocycler, and 15 rounds of amplification were conducted (94 C for 45 s, 58 
C for 30 s, 72 C for 90 s) followed by 10 min at 72 C for the final elongation. The reaction 
was run in this same manner in duplicate, and both replicates were purified on a 1% agarose gel. 
The purified fraction was subjected to an additional 15 rounds of EP-PCR following the above 
protocol to yield library 1 (notebook references 18Dec2014, 27Feb2015, 02Mar2015).  
 
Using library 1 as the template, the conditions above were matched and an additional 30 rounds 
of EP-PCR were performed. This library was also purified on a 1% w/v agarose gel, yielding 
library 2 (notebook reference 09Mar2015).  
 
The libraries were separately electroporated into S. cerevisiae using a procedure adapted from 
Wittrup and colleagues.25 The pCT302-NheI backbone was digested with NheI, 
dephosphorylated with calf intestinal phosphatase, and purified on a 1% agarose gel, yielding a 
final concentration of 409.2 ng/L. To ~1.5 g of backbone, approximately 1 g of insert was 
added, resulting in a great molar excess of insert. This mixture was divided into 4 cuvettes (0.2 
cm gap distance) and placed on ice. A 50 culture of S. cerevisiae EBY100 in YPD medium (20 g 
dextrose, 20 g peptone, 10 g yeast extract, sterile filtered) was inoculated to an OD600 = 0.1 and 
grown to reach an OD600 = 1.3. To the culture, 500 L of Tris-DTT (2.5 M DTT with 1 M Tris, 
pH 8.0) was added and the culture was shaken for 15 min at 30 C. All remaining steps were 
carried out on ice. Cells were spun down at 2400 ×g for 3 min, the supernatant removed, and the 
pellet resuspended in 12.5 mL of pre-chilled buffer E (10 mM Tris pH 7.5, 9.2% w/v sucrose, 2 
mM MgCl2). The resulting suspension was spun down at 2400 ×g for 3 min, the supernatant was 
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aspirated off, and the pellet resuspended in 1 mL buffer E. The resulting suspension was spun 
down at 2400 ×g for 3 min, the supernatant was aspirated off, and the pellet resuspended in 200 
L buffer E. Aliquots of 50 L of this solution were transferred to each cuvette, mixed 
thoroughly, incubated on ice for 5 min, and electroporation was carried out using the Sc2 setting 
on a Biorad electroporation instrument. Immediately following electroporation, cells were 
resuspended in 1 mL of YPD medium (previously warmed to 30 C) then shaken at 30 C for 1 
h. Samples were then spun down at 2400 ×g for 3 min and all transformed cells were 
resuspended in 8 mL of SD-CAA. A 10 L aliquot was plated on an SD-CAA agar plate to allow 
for determination of the number of transformants, then the remainder was added to 500 mL of 
SD-CAA and placed on a shaker at 30 C. The OD600 was determined for both library 1 and 
library 2, and then equivalent amounts of cells were mixed to yield a culture containing 
approximately equivalent representation from both libraries. This culture was grown overnight 
and aliquots were then frozen and placed at -80 C (notebook reference 25Mar2015, 27Mar2015, 
28Mar2015, 31Mar2015). 
 
To express the constructs on the surface of yeast, the library was grown overnight at 30 C in 
SD-CAA then removed from the shaker. The OD600 was determined, then sufficient library 
mixture was added to 250 mL of SG-CAA with 50 g/mL kanamycin to yield a starting OD600 of 
0.5. This culture was grown for approximately 48 h then saved at 4 C until staining (notebook 
reference 18May2015, 19May2015, 20May2015).  
 
Staining of libraries and flow cytometry analysis. Approximately 106 cells (100 L of OD600 = 
1) were placed in 1.5 mL Eppendorf tubes. Cells were pelleted by spinning at 13000 ×g for 30 s 
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and the supernatant was removed. Cells were washed with phosphate buffered saline (PBS, 8 g 
NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4) with 1% w/v bovine serum albumin (BSA) 
by adding 1 mL, mixing well, then spinning down at 13000 × g for 30 s and removing the 
supernatant. The primary agent for the stain, either the enzyme construct or the c-Myc primary 
antibody, was mixed at the desired concentration in PBS with 1% BSA. The pellet was then 
resuspended in 50 L of this primary stain solution. The primary stain was then incubated for 30 
to 90 min at room temperature. The mixture was then spun down at 13000 × g for 30 s, the 
supernatant removed, and the pellet washed with 1 mL of ice-cold PBS with 1% BSA. To the 
resulting pellet on ice, the secondary stain was added (0.5 L of the streptavidin-phycoerythrin 
solution in 50 uL of PBS with 1% BSA or 50 L of a 1:250 dilution of goat-anti-chicken 
Alexa647). The secondary stain was incubated on ice in the dark for 20 min, then pelleted and 
washed with ice-cold PBS with 1% BSA as above. The final pellets were maintained on ice until 
immediately prior to flow cytometry analysis (notebook reference 25May2015).  
 
Negative control samples were either S. cerevisiae cells from an unexpressed culture (the SD-
CAA culture) or cells from the expression culture where the primary stain element was not 
included.  
 
For flow cytometry analysis, the pellets were resuspended in 400 L of ice-cold PBS with 1% 
BSA by pipetting up and down with a micropipettor and briefly subjecting to mixing by vortex. 





Library sorting. The library was expressed as above, then 30 mL of an OD600 = 1 expression 
culture was spun down at 2500 ×g for 3 min and the supernatant removed. The pellet was 
washed by resuspending in ~10 mL of PBS with 1% BSA, then again pelleted and the 
supernatant removed. Cells were resuspended in 100 L of PBS with 1% BSA and the indicated 
CylM_Avi, Nterm-CylM_Avi, or Cterm-CylM_Avi concentration (Table 2.4). This suspension 
was incubated at room temperature for 80 min, then washed with ice-cold PBS with 1% BSA. 
The resulting pellet was resuspended in 100 L of PBS with 1% BSA with 1.0 L of 
streptavidin-phycoerythrin and incubated on ice in the dark for 25 min. The cells were again 
pelleted, washed with 1 mL of PBS with 1% BSA, and finally resuspended in 2.5 mL of PBS 
with 1% BSA immediately prior to sorting. At each sort, the top 1% of cells were selected and 
the entire sample was sorted. The resulting sorted cells were expanded in 200 mL of SD-CAA 
with 50 g/mL kanamycin and the expression/sorting procedure repeated from this culture as 
needed (notebook references 28May2015, 02Jul2018, 06Jul2018, 21Jul2018, 27Jul2015, 
03Aug2015). 
 
Sequences from the library were determined by plating a portion on an SD-CAA agar plate, then 
picking individual colonies and growing in SD-CAA for 24-48 h. Plasmids were then purified 
using the Zymoprep yeast plasmid miniprep kit. If sufficient plasmid was isolated for sequencing 
(> 50 ng/L concentration), the plasmid was directly sent for sequencing. If insufficient plasmid 
was isolated, then plasmids were used to transform individually E. coli DH10B, grown 










CylL_L_NheI_FP CCGTAT GCTAGC GAAAATC TGAGCGTTGT T  
CylL_L_cmyc_XhoI_RP TAAGTCCTCGAGTTACAGATCTTCTTCAGAAATAAGTTTTTGTTCGCAA TGTTTCAGGC T  
CylL_S_NheI_FP CCGTAT GCTAGC CTGAATA AAGAAAATCA G  
















Table 2.2. Plasmids used in this study. 
Plasmid WAV 
inventory 
Marker Insert Site Reference 
pET15b-CylLL 01117 Amp His6CylLL EcoRI, NotI 
21 
pET15b-CylLS 01118 Amp His6CylLS EcoRI, NotI 
21 
pRSF-CylM 01114 Kan CylM EcoRI, NotI 21 
pCT302-CylLL 02197 Amp/Trp Aga2-cylLL NheI, XhoI This study 
pCT302-CylLS 02198 Amp/Trp Aga2-cylLS NheI, XhoI This study 
pETDuet-Avi 02182 Amp N/A N/A M. Walker 
pETDuet-Avi-
CylM 
02194 Amp CylM NotI, BamHI This study 
pETDuet-Avi-
CtermCylM 
02196 Amp CylM(659-993) NotI, BamHI This study 
pETDuet-Avi-
NtermCylM 
02195 Amp CylM(1-658) NotI, BamHI This study 
pCola-BirA N/A Kan BirA N/A M. Walker 
pCT302-NheI 03167 Amp/Leu NheI-CylLL core N/A This study 
 
 













Table 2.4. Summary of sorting conditions 
Sorting Round Starting Population Enzyme Concentration 
(M) 
Number of cells sorted 
1 Library CylM 20 335,308 
1 Library NtermCylM 20 330,901 
2 Round 1: CylM NtermCylM 10 230,170 
2 Round 1: NtermCylM NtermCylM 10 237,827 
3 Rounds 1,2: NtermCylM NtermCylM 5 149,500 
4 Rounds 1-3: NtermCylM NtermCylM 2.5 184,825 
5 Rounds 1-4: NtermCylM NtermCylM 2.5 207,263 
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CHAPTER 3: DEVELOPMENT AND APPLICATION OF PHAGE DISPLAY OF NISIN1 
3.1 Introduction 
First described in 1985 as a useful tool for cloning,1 filamentous phage display has since 
become one of the preeminent tools for affinity maturation of peptides.2 It has been extensively 
used for antibody selection, selection of therapeutic peptides, and selection for peptides useful in 
purification of biological molecules.3 Moreover, selection environments and strategies to 
leverage peptide-displaying phage have further expanded the utility of the technique. Selections 
performed in vivo in mice have yielded organ-targeting peptides, tumor-targeting peptide 
ligands, and receptor-targeting peptides.4 Selections using magnetotactic bacteria as the target 
have unearthed peptide sequences with antimicrobial activity.5 In fact, the phage’s native 
tolerance of environmental stresses including heat, pH extremes, proteases, and even organic 
solvent suggests an almost unlimited number of selection environments are possible.6 
Despite this widespread utility, the filamentous phage itself is remarkably simple. It 
consists of a proteinaceous capsid surrounding a single-stranded genome that encodes the 
structural proteins of the phage and associated proteins necessary for the phage synthesis and 
export (Figure 3.1a).7  The native genome is approximately 6 kilobase pairs (kbp) long,8 but 
since the capsid proteins assemble around the genome it can encapsulate genomes ranging in size 
from 200 bp7 to 12,000 bp.9  One end of the phage consists of the cap proteins that emerge first 
from the bacterium host during phage export, and the other end of the phage consists of the tail 
proteins. The longer tail protein, termed pIII, is responsible for mediating infection of the host in 
wild type phage.8 This protein is also the most popular for fusion in phage display.9 Initially, 
                                                 
1 Parts of this chapter are reprinted with permission from Hetrick, K. J.; Walker, M. C.; van der Donk, W. A., 
Development and Application of Yeast and Phage Display of Diverse Lanthipeptides, ACS Cent. Sci. 2018, 4 (4), 
458-467, available at <https://pubs.acs.org/doi/abs/10.1021%2Facscentsci.7b00581>. Further permissions related to 
the work excerpted should be directed to the American Chemical Society (ACS).  
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display on pIII required a “polyvalent” display where the display peptide-pIII fusion gene was 
contained in the genome and resulted in total replacement of wild type pIII with the fusion 
(Figure 3.1b). Such a methodology often led to poor efficiency of infection and false positive 
results due to aggregation or avidity affects.10 Monovalent display systems were thus constructed 
where a “helper phage” containing a faulty phage origin provided the necessary phage genome 
but a separate “phagemid,” a plasmid consisting of an E. coli origin and a phage origin to ensure 
its DNA was also synthesized as a single strand and packaged in the virus, provided the fusion 
gene.11 Direct fusion of the C-terminus of the displayed peptide to the N-terminus of pIII allows 
display of peptides with a free N-terminus (Figure 3.1b).12 An alternative strategy takes 
advantage of the dimerization tendency of fos-jun leucine zipper proteins. This approach requires 
fusion of the C-terminus of the Jun peptide to the N-terminus of pIII, then fusion of the N-
terminus of the displayed peptide to the C-terminus of the Fos peptide, which after fos-jun 
dimerization in the periplasm results in a free C-terminus on the displayed peptide (Figure 
3.1b).10  
 These strategies for display of linear peptides have been employed for several decades 
with numerous successes, as described above. Nonetheless, the inherent metabolic instability of 
linear peptides has driven the development of the display of cyclic peptides. In contrast to linear 
peptides, cyclic peptides are resistant to proteases and more rigid, lowering the entropic cost of 
target binding.13 Hence, these macrocycles are promising for addressing difficult or 
“undruggable” therapeutic targets.14 Several means have been devised to allow display of peptide 
macrocycles (Figure 3.2c). All these approaches rely on display of a library of linear peptides 
consisting of a randomized portion and a defined residue or residues required for cyclization.  





Figure 3.1. Structure and display methodologies of filamentous phage. (a) Structure of the filamentous phage M13. 
The tail protein pIII is the most common anchor site for displayed peptides. (b) Established polyvalent, monovalent, 
and N-terminal display strategies using filamentous phage. Note that the N-terminal display strategy, allowing 
exposure of the C-terminus of the fused peptide, relies on hybridization between two leucine zipper proteins (in 
black). These two proteins are linked via disulfide bonds (illustrated in grey). (c) Strategies to display cyclized 
peptides on phage that rely on modification of linear peptides using chemical reagents. The displayed peptide is in 
red and the chemical linker is in black. Strategies include disulfide formation through interaction of two cysteines, 
nucleophilic substitution using the N-terminus of a peptide and a lysine nucleophile, and nucleophilic substitution 
using three cysteine residues as the nucleophiles. 
  
a disulfide bond between two cysteines or a nucleophilic displacement of a leaving group with a 
nucleophilic peptide residue – either the N-terminus, a lysine, or a cysteine.15 These 
methodologies have yielded products that can disrupt protein-protein interactions and illustrate 
the potential utility of macrocycle display systems.16 However, these approaches do not leverage 
enzymatic machinery that makes cyclic natural products despite the potential advantages of 
highly regio- and stereo- selective processes that lead to molecular diversity and stability.  
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We therefore decided to develop a phage display methodology that leverages 
biosynthetic, macrocycle-generating enzymes to create a library of cyclized peptides. We chose 
to execute the scheme with nisin as a first test case. Nisin is a class I lanthipeptide that has been 
extensively studied and structurally characterized since its first description in 1928, and its 
biosynthesis has been elucidated (Figure 3.2).17 The biosynthetic machinery features a LanB 
enzyme, NisB, that activates Ser/Thr residues in the substrate peptide through glutamylation. 
Unique to the class I lanthipeptides, activation of the Ser/Thr residue uses glutamyl-tRNA as the 
glutamyl source.18 NisB then also catalyzes elimination of the glutamyl group from the 
intermediate to yield dehydroalanine/dehydrobutyrine residues. An independent enzyme LanC, 
termed NisC in nisin biosynthesis, then installs the thioether linkages. Proteolysis of the leader 
peptide by a LanP enzyme, termed NisP for nisin’s biosynthesis, liberates the mature, active 
product. The action of NisB, NisC, and NisP on the precursor peptide NisA thus yields the 
mature product nisin A, and this wealth of knowledge makes it an attractive test case since there 
are host of proven characterization methods.17 Moreover, its biosynthesis has previously been 
reconstituted in E. coli,19 making it well-suited for an E. coli-based display system. 20 Finally, its 
native target, lipid II (inset Figure 3.2), is synthetically accessible21 and could therefore be used 




Figure 3.2. Biosynthesis of nisin, detailing its conversion from a linear peptide to the final product containing 5 
peptide macrocycles. Inset: the native target, lipid II. Note that formation of at least the first two rings of nisin are 
required for binding to lipid II.22 Dha = dehydroalanine. Dhb = dehydrobutyrine. 
 
3.2 Results 
3.2.1 Display scheme 
A scheme for phage display of lanthipeptides was developed (Figure 3.3). Since nisin 
analogs that are extended at the N-terminus by even a single Ala23 have been shown to be 
inactive,24,25 presumably due to interference with lipid II binding, C-terminal display would 
likely not be useful to select for variants that bind to lipid II. We therefore aimed to display nisin 
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on phage by genetically fusing the C-terminus of the nisA gene to a gene that encodes an N-
terminally truncated phage protein pIII (residues 205-406) of the filamentous phage M13, 
thereby leaving the N-terminus of nisin free. Filamentous phage assembles in the periplasm of E. 
coli, and the required proteins must therefore be exported into the periplasmic space. It was 
previously demonstrated that the Sec-mediated translocation of nisin cannot export fully 
modified nisin precursor peptide,26 and hence the Tat pathway, which is known to translocate 
cytoplasmically folded proteins,27 was chosen for export in this study. The desired tat-HisTag-
nisA-truncpIII construct was assembled into a phagemid – a plasmid containing both an E. coli 
origin and a phage origin, which ensures it is packaged as single-stranded DNA in the mature 
phage. The modification enzymes NisB and NisC were encoded on a separate modification 
plasmid. Helper phage M13KO7 was used to supply the remaining required phage proteins, and 
expression of these components was envisioned to yield phage displaying modified NisA. 
Addition of the leader peptidase NisP in vitro was then anticipated to remove the leader peptide, 
yielding phage displaying nisin A and containing the associated nisA genetic material. To 
demonstrate that the display scheme functions as anticipated, we chose first to demonstrate that 
the modified nisin can be exported to the periplasmic space and second that it indeed assembles 
on the phage. 
 
3.2.2 Export of modified NisA into the periplasm 
 Export of fully modified lanthipeptides into the E. coli periplasm has not previously been 
reported. Three pathways for peptide export are known: the signal recognition particle pathway 




Figure 3.3. Scheme for the display of nisin on phage. The NisA construct contains the Tat signal peptide-
lanthipeptide precursor-phage protein pIII fusion. NisB/C is expressed from the modification plasmid. After post-
translational modification by NisBC in the cytoplasm, the Tat-HisTag-NisA-pIII is exported to the periplasm where 
the signal sequence is proteolytically removed. As in wild type pIII, the modified NisA-pIII then inserts into the 
inner membrane awaiting phage assembly. The final phage is then assembled and secreted into the culture medium. 





is a co-translational pathway and hence unsuitable for lanthipeptide export since the peptide must 
be present in the cytoplasm where the modification enzymes act. The Sec pathway, as described 
above, has been shown to export only partially modified nisin. The TAT pathway, therefore, 
seemed the best export pathway to try. Other characteristics of the TAT pathway also inspired 
confidence. It is the least efficient of the three pathways, which would allow the most time for 
NisB/C to modify the precursor peptide in the cytoplasm. It also is capable of exporting large, 
folded proteins many times bigger than nisin, so it should be able to accommodate the globular, 
fully modified nisin.27 Finally, its use in phage display has been previously described.27 We 
therefore determined to attempt export with the TAT pathway. We also attempted export with 
the Sec pathway to compare its results to those of the TAT pathway. 
 
Figure 3.4. Schemes to compare the export product of the (a) Sec versus the (b) Tat pathways.  
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 Two constructs were created to assess the use of these pathways (Figure 3.4). The first 
construct, NisAHisTag-pTSP3H, contained a gene encoding a fusion of the Tat signal peptide-
HisTag-NisA-HisTag. This construct is identical to the construct for phage display described in 
the scheme above with the exception that the pIII protein is replaced with a HisTag. The pIII 
protein, when exported to the periplasm, inserts into the inner membrane and would complicate 
purification.29 A construct to test the Sec pathway, NisA-pJF3H, was created by cloning histag-
nisA into the pJF3H phagemid. This creates a gene encoding Sec signal peptide-Fos protein-
HisTag-NisA (note that this plasmid also encodes Jun-pIII, where the Jun and Fos proteins 
dimerize via disulfide bonds to allow C-terminal peptide display, as illustrated in Figure 3.1b). 
Both constructs were coexpressed with the modifying enzymes NisB/C. The periplasmic portion 
was then separated from the cytoplasmic portion using osmotic shock, and both fractions were 
subjected to purification by nickel-immobilized metal affinity (Ni-IMAC) chromatography. The 
leader peptide of the IMAC-purified construct ends with an arginine residue and the final residue 
of the core peptide of nisin is a lysine. Since the internal lysine in nisin is adjacent to a ring and 
therefore resistant to proteolysis, the purified isolate from the periplasm or cytoplasm was 
digested with trypsin to liberate the nisin core, and the digested isolates were analyzed via 
MALDI-TOF MS. The mass spectrometry data demonstrated that the Tat pathway yielded fully 
and partially dehydrated nisin in the periplasmic space but no nisin-related species in the 
cytoplasmic space, whereas the opposite was observed for the Sec pathway (Figure 3.5; note that 




Figure 3.5. MALDI-TOF MS of the trypsin-digested periplasmic and cytoplasmic isolates from Sec and Tat 
pathways. (a) the Sec pathway shows peaks corresponding to fully dehydrated NisA in the cytoplasmic fraction; 
however, the periplasmic fraction yielded no nisin-related peaks. The * indicates two unidentified peaks that may 
arise from the Fos-Jun peptide. (b) The periplasmic Tat pathway yields primarily 7-fold dehydrated NisA, although 
some fully dehydrated NisA is also observed (predicted mass of nisin: 3352.5 Da; observed mass: 3353.1; * 




Since the Tat pathway appeared to successfully export fully dehydrated NisA into the 
periplasm while the Sec pathway did not, we chose to analyze the Tat-exported peptide further. 
Bioactivity of the isolate against Bacillus subtilis ATCC 6633 demonstrated that the periplasmic 
isolate is cyclized since installation of the thioether crosslinks is required for bioactivity (Figure 
3.6). Comparison of the zone of growth inhibition displayed by the periplasmic isolate to that of 
authentic nisin was used to determine the approximate amount of nisin that is exported to the 
periplasm. Correlation of this value to the number of virions produced from a parallel culture 
suggests that about 20 molecules of nisin are produced in the periplasmic space for each phage. 
Since each phage contains 3-5 copies of pIII, these data show that sufficient nisin export is 
achieved to ensure that each virion produced displays nisin. 
 
Figure 3.6. Bioactivity analysis of the Tat-exported periplasmic isolate compared to the bioactivity of a known 
concentration of authentic nisin. 
 
3.2.3 Assembly of the Tat-HisTag-NisA-truncated pIII fusion peptide on phage 
We next investigated whether the modified Tat-HisTag-NisA-truncated pIII fusion peptide 
indeed assembles on the phage. Mass spectrometric analysis of the phage-displayed construct 
proved not possible. We therefore produced two varieties of phage: the first prepared with co-
expression of the modifying enzymes NisB/NisC, termed modified-NisA phage, and the second 
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produced without the expression of the modifying enzymes, termed linear NisA phage. The 
precursor peptide includes a His6-tag at the N-terminus of the NisA leader peptide, and thus 
SDS-PAGE of the phage samples followed by Western blotting with an anti-His-tag antibody 
showed the same band in both samples prior to digestion with NisP (Figure 3.7), suggesting that 
the modified and linear constructs are assembled on the phage. Next, we incubated both phage 
samples with the mature NisP protease. The activity of NisP is severely diminished for substrates 
without the thioether rings installed,30,31 predicting that NisP treatment would result in 
disappearance of the HisTag-immunoblotted band in the Western blot of modified NisA phage, 
whereas the band should be largely retained in the linear NisA band. Densitometric analysis for 
both modified NisA phage and linear NisA phage demonstrated that the band retained 70±20% 
(n = 3) of the initial density upon NisP treatment for linear NisA phage, whereas the modified 
NisA phage maintained only 12±9% (n = 3) of the initial density following NisP treatment 
(Figure 3.7c). Thus, these data show a statistically significant difference between the two 
samples (p = 0.004) that suggests that modified phage displays a significant fraction of cyclized 
NisA. This conclusion is further supported by the binding of the modified phage to immobilized 




Figure 3.7. Demonstration that the modified construct is assembled on the phage using Western blot. (a) The gene 
construct used in this study and the scheme demonstrating how NisP can be used to query whether the peptide 
assembled on the phage is modified. (b) Representative Western blot demonstrating that the HisTag is efficiently 
removed when the modified NisA-displaying phage is incubated with NisP, whereas the HisTag is largely retained 
in the control reaction where linear NisA-displaying phage is incubated with NisP. (c) Scatter plot showing 
comparison of the percent of initial density retained in triplicate for modified NisA- versus linear NisA-displaying 
phage (p = 0.004). 
 
3.2.4 Screening of a peptide library for binding to lipid II 
We next sought to establish that a library of nisin variants could be screened for a specific 
activity. We created a library of variants of the A- and B-rings of nisin through randomization of 
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the five residues within these rings using the NNK codon (K = G/C; Figure 3.8a) that can encode 
all 20 amino acids. Synthetic oligonucleotides were ordered and assembled into the phagemid 
vector to create the library, and the library was then subjected to Illumina sequencing. Deep 
sequencing revealed the library encoded 1.2×106 variants out of a theoretically possible 3.4×107 
(205). The deep sequencing data also allowed characterization of the library. A plot of the 
number of unique peptides versus the number of times the peptide was sequenced depicts how 
many of the peptide sequences are highly represented (Figure 3.8b). A plot of the number of 
times a peptide was sequenced against the percent of total sequences depicts how many times the 
proportions of the total sequences appear in the sequence data (Figure 3.8c). In both of these 
plots, a sharply depleting curve is suggestive that fewer sequences are overrepresented in the 
unselected library. Finally, a plot of the amino acid encoded at each randomized position 
visualizes the relative amino acid/stop codon representation at that position (Figure 3.8d). The 
distribution among amino acids in this library at each position was fairly even and roughly 
corresponded to the number of NNK codons representing each amino acid. Taken together, the 
data suggest that the bulk of the library is evenly represented, and each amino acid is relatively 
evenly represented at each randomized position. The library was thus judged to be of sufficient 
quality to continue with the selection. Additionally, constructs encoding wild type nisin A were 
present in the library. Therefore, a successful lipid II-binding selection should result in 




Figure 3.8. Creation and deep sequencing analysis of the nisin A and B ring library. (a) The residues in nisin 
encoded by the NNK codon. (b) The distribution of the number of times amino acid sequences were identified in the 
library. (c) Percent of the total library represented by unique amino acid sequences. (d) The proportion of each 
position in the library that encodes amino acids encoded by the NNK degenerate codon. 
 
To determine whether phage bearing lipid II-binding nisin variants could be enriched, we 
developed a selection strategy (Figure 3.9a). We digested the phage with NisP to remove the 
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leader peptide. We then incubated the phage library with biotinylated lipid II, pulled down the 
bound variants using streptactin resin, washed the resin to remove unbound phage, and released 
the bound variants through incubation with nisin A. The eluted phage were used to infect E. coli, 
and the plasmids were isolated and subjected to deep sequencing. As a control, the experiment 
was repeated without the addition of biotinylated lipid II (Figure 3.9b). This control will identify 
variants enriched in the selection due to nonspecific factors, such as adherence to the streptactin 
resin or the wall of the selection vessel. To avoid the influence of codon bias introduced through 
repeat amplification of phage libraries in E. coli, only a single round of selection was 
performed.32 Both the selection and control were performed in triplicate to allow statistical 
comparison of enrichment relative to the unselected initial library. 
 
Figure 3.9. Diagram of the selection strategy used to enrich lipid II-binding nisin variants. (a) The selection strategy 
for identifying nisin variants that bind lipid II. (b) The control selection strategy for identifying nisin variants that 
are enriched due to factors other than binding lipid II. 
 
Following the single round of selection, comparison of the variant frequencies in the lipid 
II-binding selection to the initial variant frequencies in the library prior to selection revealed that 
while the vast majority of variants were not enriched or were depleted, four variants were more 
than 2-fold enriched and did not appear in the control selection lacking lipid II. A T-test was 
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used to determine the statistical significance of the enrichment, and all variants that were also 
significantly enriched in the control selection were removed from the analysis. The nisin A-
bearing phage was the second most enriched of these variants (9-fold enriched; p=0.03) when 
compared to the initial library, whereas in the control selection, nisin A-bearing phage was not 
significantly enriched. The enrichment of wild type nisin A from the library demonstrates that 
the selection successfully isolated a lipid II binding molecule.  
 
Figure 3.10. Results of the selection for lipid II-binding nisin variants. (a) Sequences that were significantly 
enriched in the selection and that were not enriched in the control selection. Note that the 9-fold enriched variant is 
wild-type nisin A. (b) The amino acid sequence of the most-enriched variant. (c) MALDI-TOF MS of the variant 
from (b) after heterologous production in E. coli, purification, and NisP-digestion. Calculated mass of 7-fold 
dehydrated variant: 3478.6 Da. Observed mass: 3479.7 Da. 
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Three other variants were also enriched in the selection, one of which was enriched more 
than nisin A (Figure 3.10b). This variant, I4F/L6P/P9M/G10L, was thus chosen for further 
characterization. It was produced in E. coli through coexpression of the corresponding His6-
tagged NisA variant with NisB and NisC, purified and digested with NisP, and characterized via 
MALDI-TOF MS (Figure 3.10c). The mutations were well-tolerated by the processing enzymes, 
yielding a primarily 7-fold dehydrated species. To determine whether the thioether-linked 
macrocycles were installed, a reaction of the processed peptide with N-ethylmaleimide (NEM), 
was performed. No NEM adducts were observed, indicating the Cys residues are engaged in 
thioethers (Figure 3.11a). Bioactivity assays demonstrated that the product did not possess any 
antimicrobial activity against Lactococcus lactis NZ9000 (Figure 3.10b). We therefore 
determined whether the ring topology matched that of wild type nisin. As noted above, the 
peptide was successfully digested by the endoproteinase NisP, suggesting that the rings are 
formed correctly. Tandem mass spectrometry analysis of the variant revealed a very similar 
fragmentation pattern as nisin A (Figure 3.11c,d), further confirming that the ring topology of the 
variant matches that of nisin. It is therefore likely that the simultaneous variation of four of the 
five residues in the A and B ring disrupts the correct assembly of a pore-forming lipid II:nisin 




Figure 3.11 (following page). Further characterization of the most-enriched nisin variant from the selection. (a) N-
ethylmaleimide analysis of the modified variant. (b) Bioactivity analysis of the modified variant (abbreviated 
FSP.ML) compared to that of wild type nisin A. (c) LC-MS/MS analysis of wild type nisin A. (d) LC-MS/MS 





Figure 3.11 (continued). 
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Because of the low solubility of this variant in aqueous media, we were unable to 
investigate its interaction with lipid II using common techniques including thin-layer 
chromatography35 or isothermal titration calorimetry.36 We therefore assessed the interaction 
using 31P NMR spectroscopy in perdeuterated dimethyl sulfoxide. Previous 31P NMR 
characterization of nisin’s interaction with lipid II (Figure 3.12a) in this solvent revealed that the 
pyrophosphate peaks shift upfield upon nisin binding.22 We performed similar experiments by 
mixing either nisin A or the nisin variant with lipid II and acquiring 31P NMR spectra. Two new 
31P NMR resonances were observed for both nisin (Figure 3.12b) and the variant (Figure 3.12c), 
confirming both compounds bind to lipid II. Consistent with the previous study,22 both new 
resonances arising in the nisin/lipid II spectra were shifted upfield. However, only one of the 
new resonances arising for the variant was shifted upfield, whereas the other was shifted 
downfield. This suggests that the variant indeed forms a complex with lipid II but in a different 




Figure 3.12. Assessing the lipid II-binding of nisin or the enriched nisin variant using 31P NMR spectroscopy. (a) 
The structure of lipid II. Note the pyrophosphate moiety which should give rise to two resonances in 31P NMR 
spectroscopy. (b) Analysis of just lipid II and different mixtures of lipid II and wild type nisin A, showing two new 
resonances arise when nisin binds some of the lipid II. (c) Analysis of just lipid II and different mixtures of lipid II 
and the enriched nisin variant, again showing two new resonances arise when the nisin variant binds some of the 
lipid II. 
 
3.3 Discussion and outlook 
We were able to achieve phage display of nisin A, a class I lanthipeptide with a 
demanding biosynthetic pathway since it requires dedicated dehydratase and cyclase enzymes 
with the former having an unusual requirement of glutamyl-tRNA as cosubstrate. In our system, 
we used the Tat export pathway and we demonstrated that NisBC could correctly and efficiently 
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modify a NisA fusion peptide inside the cytoplasm prior to export into the periplasm. This 
finding contrasts with a very recent report on attempts at N-terminal phage display of nisin using 
the Sec pathway that resulted in unmodified NisA being exported too efficiently into the 
periplasm.37 In this report by Urban et al., the authors then moved to C-terminal display, which 
was demonstrated to result in successful export of modified peptides into the periplasm.37 Since 
nisin analogues with amino acid or peptide extensions at the N-terminus have been shown to be 
inactive,24,38,39 C-terminal display, while very powerful to select binders to non-native targets, 
likely cannot be used for selecting lipid II binders. With the ability to remove the N-terminal 
leader peptide with NisP thus exposing the native nisin N-terminus, our N-terminal phage 
display method of nisin using the Tat export pathway is complementary with the recently 
reported C-terminal display using the Sec pathway. The latter pathway was also used to C-
terminally display libraries of the prochlorosin family of lanthipeptides that were made by the 
highly substrate tolerant class II ProcM enzyme,37 which we have not investigated. These 
displayed prochlorosin variants were then selected for binders to urokinase plasminogen 
activator and streptavidin.37  
These complementary phage display strategies form part of a growing repertoire of 
selection methodology leveraging RiPP biosynthetic machinery, including yeast display,20 
bacterial display,40 and a two-hybrid system41 (Figure 3.13). In addition to these methodologies, 
an mRNA-display technique has been proposed as another promising methodology and much of 
the work underlying its use as a selection platform has been completed.42 The variety of 
lanthipeptide systems employed in these studies (class I – NisBC, class II – LctM, HalM2, 
ProcM) suggests that the methods are generally applicable. Such display methods allow full 
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exploration of the remarkable substrate tolerance of RiPP biosynthetic enzymes well beyond 
previous site saturation mutagenesis studies.  
 
Figure 3.13. Demonstrated selection methodologies leveraging RiPP biosynthetic machinery. (a) C-terminal phage 
display of nisin described in this chapter, allowing the leader peptide to be cleaved in vitro using NisP. (b) N-
terminal yeast display, demonstrated with the lanthipeptides haloduracin and lacticin. (c) N-terminal phage display 
of artificial peptides, accomplished using the ProcM enzyme to install the modifications. (d) A reverse two-hybrid 
system where selection is performed inside E. coli. (e) A C-terminal bacterial display methodology, which was 
demonstrated in the native nisin producer Lactococcus lactis.  
 
 Within this context of methodologies, the C-terminal display of nisin occupies an unique 
position. It is the only methodology that has been demonstrated to be compatible with the use of 
the native protease, although the reverse two-hybrid system (Figure 3.13d) and the bacterial 
display methodology (Figure 3.13e) theoretically are also compatible with the addition of the 
associated protease. It is therefore also the only methodology that allows the displayed peptide to 
bind its native target when binding requires a free N-terminus. Given the high tolerance of the 
phage particle to pH or temperature extremes, it can be used in a wider array of selection 
environments than the reverse two-hybrid system, where the selection is performed in the E. coli 
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intercellular milieu, or the bacterial display methodology, where selection is limited to 
environments that maintain the integrity of the Lactococcus lactis outer membrane.  
 These unique attributes suggest several possible future uses of the system. First, the 
phage display system could be expanded to other classes of RiPPs. The lasso peptides are a class 
of RiPP that have both many potential applications, including using siderophore receptors to 
access the internal region of a cell,43 and a high degree of chemical diversity.44 Moreover, their 
biosynthesis necessitates removal of the leader region of the peptide in order to form the lariat 
knot,45 and they are thus limited to display strategies that do not rely on tethering to the N-
terminus. The C-terminus, however, is accessible in some lasso peptide variants as a tethering 
point without impacting their biosynthesis.46 Therefore, the phage display platform developed 
here could be employed to display lasso peptides (Figure 3.14a) and leveraged to select lasso 
peptide variants with affinity for discrete siderophore receptors. This in turn could lead to the 
development of species- or even strain-specific antimicrobial compounds or sideromycins.47 A 
second potential application is in optimizing known RiPPs to improve their stability or pH-
tolerance (Figure 3.14b). In this approach, a selection similar to the one we performed would be 
used except the peptide-displaying phage would be exposed to extreme conditions prior to 
performing the selection. A third suggested application of this methodology is with the 
lanthipeptide duramycin. Duramycin is a class II lanthipeptide that binds 
phosphatidylethanolamine, and it has been employed as an imaging agent in vivo to detect 
necrotic cells – cells that display phosphatidylethanolamine.48 Display of a library of duramycin 
variants (Figure 3.14c) that were selected using phosphatidylserine as the target could allow 
discovery of a new class of imaging agents that can detect apoptotic cells, which display 
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phosphatidylserine.49 Similar selections could yield a host of other phospholipid-targeting 
peptides.  
 
Figure 3.14. Proposed future uses of the phage display system. (a) Display of the lasso peptide microcin J25 could 
allow selection of siderophore receptor-binding RiPPs. (b) Exposure of the peptide-displaying phage to extreme 
environments followed by selection would allow identification of lanthipeptides with improved stability. (c) Display 
of a phosphatidylethanolamine-binding lanthipeptide could allow selection for lanthipeptides with alternative 
phospholipid specificity. Note that it is unknown which positions would actually change in such a selection – the 




 Applications of this methodology and the other lanthipeptide display methodologies are 
essentially limitless, although there are many remaining challenges. The diversity of the RiPP 
family of natural products is rapidly expanding,44 so expanding these engineering approaches to 
other RiPP families will maximize their usefulness. Theoretically, any RiPP that can be made in 
E. coli will work with this display system, yet validating that the desired and modified peptide is 
displayed remains a challenge since isolation and characterization of the displayed peptide from 
phage has proven impracticable. This work relied on the specificity of the nisin protease NisP 
coupled with a Western blot to overcome this challenge, but in cases where similar strategies 
cannot be applied a selection with the native target may be the only means to suggest whether the 
displayed peptide is modified and active. Another ongoing challenge is developing a selection 
methodology to maximize multiple desired parameters. In this study, we were able to find a nisin 
variant that binds lipid II, and unlike nisin it did not contain a hydrolysable dehydroalanine 
residue in the A-ring, which is a vulnerability for application of nisin in many settings. However, 
its solubility was significantly less than wild type nisin, and it did not maintain any detectable 
bioactivity, making it overall less optimal than wild type nisin for most applications. Future 
selection methods need to seek out means to optimize a desired parameter while maintaining the 
current desirable parts of the natural product’s profile. This may require a complex selection 
strategy involving multiple rounds of selection and counter-selection. Alternatively, it may be 
best accomplished through a brute-force approach where all the variants found in a selection are 
screened for activity, solubility, and other desired properties. Surmounting these challenges will 





3.4 Materials and methods  
Commercial materials. All chemicals were purchased from ThermoFisher Scientific 
(Pittsburgh, PA) unless otherwise noted. Luria-Bertani (LB) and Terrific Broth (TB) were 
purchased from Fisher Scientific. Streptactin resin was purchased from IBA Lifesciences 
(Goettingen, Germany). Restriction enzymes and Phusion DNA polymerase were purchased 
from New England Biolabs (Ipswich, MA). Plasmid mini-prep kits were purchased from Qiagen 
(Valencia, CA). Amicon centrifugal concentrators were purchased from Millipore (Billerica, 
MA). The Nextera XT index kit was purchased from Illumina (San Diego, CA). DNA 
oligonucleotides and synthetic DNA gene fragments (gBlocks) were purchased from Integrated 
DNA Technologies (Coralville, IA). Calculated and observed m/z values tandem mass 
spectrometry data are listed in Table 3.1. Sequences of oligonucleotide primers are provided in 
Table 3.2, and sequences of gBlocks are given in Table 3.3. Table 3.4 lists all plasmids and 
phagemids used or constructed in this study. 
 
Bacterial strains. Escherichia coli DH10B-T1R was used for plasmid construction, BL21 
(DE3)-T1R was used for heterologous protein production, and SS320 was used for phage 
production. Bacillus subtilis ATCC 6633 was used to test the biological activity of nisin isolated 
from the periplasm. Lactococcus lactis NZ9000 was used to test the bioactivity of the enriched 
nisin variant. 
 
Construction of plasmids for phage display. The gene encoding the fusion protein consisting 
of the Tat signal sequence-Hexahistidine tag-NisA-pIII was constructed in the phagemid 
pTSP3H.10 The hexahistidine tag-NisA fusion was cloned from pRSF-NisA (Table 3.4) using 
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primers NisA FP pJF3H BssHII and NisA RP NotI pJF3H (Table 3.2). This DNA fragment was 
ligated into phagemid pJF3H (provided by Jun Yin, University of Chicago) digested with BssHII 
and NotI to yield the construct NisA-pJF3H. A synthetic gene block containing the Tat signal 
sequence from the trimethylamine N-oxide reductase protein (ssTorA) (Table 3.3) was used as 
template to clone the tat signal sequence with primers TorA_FP and TorA_RP. The pJF3H 
construct was digested with restriction enzymes EcoRI-HF and SbfI-HF and assembled with the 
cloned signal sequence by an isothermal assembly. The resulting construct was amplified in two 
pieces with primers KJH_NisA_pTSP3H_FP and KJH_NisA_pTSP3H_RP to amplify the 
hexahistidine-NisA fusion gene and primers KJH_pTSP3H_FP and KJH_pTSP3H_RP to 
amplify the phagemid backbone including the C-terminal truncated pIII (residues 274-424). The 
two fragments were then assembled by isothermal assembly to produce phagemid pTSP3H-NisA 
(notebook reference 04Dec2014, 05Dec2014, 08Jan2015, 10Jan2015, 16Jan2015). 
To make the phagemid with a hexahistidine tag in place of pIII, phagemid pTSP3H-NisA was 
amplified using primers nopIII_R and nopIII_F. The resulting product was assembled in an 
isothermal assembly reaction to yield the final product, pTSP3H_no_pIII-NisA (14Jan2017, 
16Jan2017, 23Jan2017). 
The plasmid pAT7C-NisBC (Table 3.4) contains genes encoding NisB and NisC under a T7 
promoter and the gene encoding the T7 polymerase under the arabinose promoter. The gene 
encoding T7 RNA polymerase (T7RNAP) was cloned out of pBR33-T7RNAP using primers 
T7_pBADHisA_RP and T7_pBADHisA_FP. The resulting product was assembled with 
pBAD/HisA (Invitrogen) digested with HindIII and NcoI in an isothermal assembly to yield 
pBAD/HisA-T7RNAP. The region encoding T7RNAP and the araC gene was cloned out of this 
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plasmid using primers T7polAra_pACYC_RP and T7polAra_pACYC_FP. The resulting DNA 
was assembled in an isothermal assembly with pACYC-NisBC (Table 3.4) digested with EcoNI. 
The resulting construct was termed pACYC-NisBCT7. This construct was digested with NheI 
and XbaI to remove the p15a origin, and the digested product was assembled with the colA 
origin cloned out of pColA using primers ColA_FP and ColA_RP to yield pAT7C-NisBC 
(notebook references 02Oct2014, 17Oct2014, 19Oct2014, 12Mar2015). 
The gene encoding NisP (residues 195-651) was cloned from Lactococcus lactis ATCC 11454 
using primers NisPf and NisPr. The backbone pRSFDuet was amplified by PCR using primers 
NisPbbf and NisPbbr. The two fragments were assembled via an isothermal assembly reaction to 
yield pRSF-NisP (notebook reference 09Feb2017, 10Feb2017, 13Feb2017). 
Construction of plasmid encoding the enriched NisA variant. The gene encoding the NisA 
I4F/L6P/P9M/G10L variant, termed the FSP.ML variant to denote the 3 residues in the A-ring 
and the 2 residues in the B-ring, was ordered as the two oligonucleotides FSPML_f and 
FSPML_r. These were annealed and amplified via PCR with the primers extend_f and extend_r. 
The plasmid pRSF-NisA was digested with SacI and BstB1, and the digested plasmid and 
amplified oligonucleotide were combined in an isothermal assembly to yield pRSF-FSPML 
(notebook references 28Aug2017, 30Aug2017). 
Expression and purification of modified NisA-displaying phage. E. coli SS320 was 
transformed with pTSP3H-NisA and pAT7C-NisBC. An overnight culture in 2xYT containing 
25 g/mL chloramphenicol, 100 g/mL ampicillin, 10 g/mL tetracycline, and 2% w/v glucose 
was used to inoculate at 1% v/v an expression culture of 2xYT (100 mL) containing 25 g/mL 
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chloramphenicol and 100 g/mL ampicillin. The cultures were grown at 37 °C with shaking at 
220 rpm to OD600 = 0.4. Helper phage M13KO7 stock (at ~10
12 pfu/mL) was then added at a 
ratio of 1:500 (v:v) helper phage:culture media. The culture was returned to the shaker at 37 °C 
with shaking at 220 rpm for 1 h to allow phage transfection. The culture was removed from the 
shaker and kanamycin was added to 60 g/mL to remove any uninfected E. coli. At the same 
time, production of Tat-NisA-pIII fusion, T7RNAP, and NisB/C was induced by adding 
arabinose to 0.04% w/v and IPTG to 1 mM. The culture was returned to the shaker at 27.5 °C 
with shaking at 220 rpm for 24 h to produce phage (notebook reference 27Jan2016).  
Following production of phage, the cells were pelleted by centrifugation at 14,000 × g for 15 
min. The supernatant was poured off and subjected to a second round of centrifugation at 14,000 
× g for 15 min to pellet any remaining cellular debris. The resulting supernatant was again 
decanted. A solution of 2.5 M NaCl with 20% w/v PEG8000 was added to the decanted 
supernatant at a ratio of 1:4 (v:v). This sample was mixed well and placed on ice for at least 12 h 
to allow the phage to precipitate. After 12 h on ice, the phage was pelleted by centrifugation at 
10,500 × g for 10 min. The supernatant was aspirated off and the pellet was resuspended in 2 mL 
of phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4, pH 7.4). This was then centrifuged at 14,000 × g for 15 min to pellet insoluble debris 
and the supernatant was removed via pipet into a fresh vial. The phage was precipitated a second 
time by adding 2.5 M NaCl with 20% w/v PEG8000 at a ratio of 1:4, mixing well, and placing 
on ice for at least 2 h. The phage was again pelleted by centrifugation at 10,500 × g for 10 min, 
the supernatant was aspirated off, and the phage was resuspended in 500 mL of PBS. The 




Sterility of the phage was assured through sterile-filtering through a 0.22 m filter (notebook 
reference 29Jan2016).  
Expression and purification of linear NisA-displaying phage. The procedure exactly matched 
that above except that E. coli was not co-transformed with pAT7C-NisBC. Consequently, 
chloramphenicol was also omitted from the culture solutions (notebook reference 04May2017, 
05May2017).  
Expression and purification of hexahistidine tag-NisA-hexahistidine tag from the 
periplasmic space. E. coli SS320 was transformed with the pTSP3H_no_pIII-NisA and pAT7C-
NisBC. An overnight culture in 2xYT containing 25 g/mL chloramphenicol, 100 g/mL 
ampicillin, and 2% w/v glucose was used to inoculate at 1% a 1.5 L expression culture of 2xYT 
(1.5 L) containing 25 g/mL chloramphenicol and 100 g/mL ampicillin. The cultures were 
grown at 37 °C with shaking at 200 rpm to OD600 = 0.6. Production of Tat-His6-NisA-His6, 
T7RNAP, and NisB/C was induced by adding arabinose to 0.04% w/v and IPTG to 0.5 mM. The 
culture was returned to the shaker at 27.5 °C with shaking at 220 rpm for 12 h. Cells were 
harvested by centrifugation at 4,000 × g for 15 min and then placed on ice (notebook references 
07Sep2016, 08Sep2016).   
The method for the isolation of the periplasmic space was adapted from a previously described 
procedure.12 The entire 10.9 g cell pellet from 1.5 L of culture was suspended through gentle 
swirling in 500 mL of ice-cold 0.75 M sucrose with 0.1 M Tris-Cl (pH 7.75) and 100 g/mL Hen 
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Egg lysozyme. To this suspension, 1 L of ice-cold 1 mM EDTA was added and the resulting 
liquid was mixed gently and allowed to rest on ice for 10 min. After 10 min, 53 mL of 1 M 
MgCl2 was added, the suspension was again mixed gently and allowed to rest on ice for an 
additional 10 min. The resulting spheroplasts were pelleted at 4000 × g for 15 min and the upper 
90% of the supernatant was decanted gently. This supernatant represents the periplasmic 
fraction. To this isolated periplasmic fraction, sodium phosphate was added to 100 mM, Tris was 
added to 10 mM, and urea was added to 8 M urea. The pH was adjusted to 8.0, and the entire 
solution was passed over a nickel-iminidiacetic acid (Ni-IDA) resin column. Following loading, 
the column was washed with 10 column volumes of Buffer A (8 M urea, 100 mM phosphate, 10 
mM Tris-Cl, pH 8.0). Then the column was washed with Buffer A adjusted to pH 6.3 for 5 
column volumes. The protein of interest was eluted from the column with 5 column volumes of 
Buffer A adjusted to pH 4.5. The eluent from the Ni column was desalted using a C4 SPE 
column and lyophilized to dryness (notebook reference 09Sep2016).  
The resulting sample was resuspended in 400 L ddH2O, and then 80 L of this was combined 
with 10 L of 200 mM Tris-Cl (pH 7.5)/10 mM CaCl2 and 10 L of 0.1 mg/mL trypsin and 
placed at 30 °C for 9 h to ensure complete digestion (notebook reference 20Oct2016).  
Expression and purification of fos-NisA from the periplasmic space. E. coli SS320 was 
transformed with pJF3H-NisA and pACYC-NisBCT7. An overnight culture in 2xYT containing 
25 g/mL chloramphenicol, 100 g/mL ampicillin, and 2% w/v glucose was used to inoculate at 
1% an expression culture of 2xYT (1.5 L) containing 25 g/mL chloramphenicol and 100 g/mL 
ampicillin. The cultures were grown at 37 °C with shaking at 200 rpm to OD600 = 0.6. Production 
of T7RNAP and NisB/C was induced by adding arabinose to 0.02% w/v and the culture was 
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allowed to continue to grow for an addition 1.3 h and the OD600 = 0.8, then IPTG was added to 1 
mM concentration. The culture was returned to the shaker at 27.5 °C with shaking at 220 rpm for 
15 h. Cells were harvested by centrifugation at 7,110 × g for 20 min and then placed on ice.  The 
periplasm was then extracted as above except the lysozyme was not included (notebook 
reference 03Sep2014, 13Jan2015).  It should be noted here that since a reductant was not 
included, this procedure may result in co-purification of the Jun-pIII fusion protein due to 
dimerization of Jun-Fos. 
Expression and purification of the cytoplasmic fraction of hexahistidine tag-NisA-
hexahistidine tag or fos-NisA. Using cell pellets subjected to the periplasmic isolation 
procedure detailed above, the cytoplasmic fraction was isolated by resuspending the cell pellet at 
5 mL/g of cell paste in LanA buffer B1 (20 mM sodium phosphate, 500 mM sodium chloride, 
0.5 mM imidazole, and 6 M guanidinium chloride, pH 7.5). The cell pellet was lysed by 
sonication (50% amplitude, 1 s on, 2 s off, 6 min total time) then the insoluble matter was 
pelleted by centrifugation at 25,000 × g for 25 min at 4 °C. The supernatant was then loaded on 5 
mL of Ni-IDA resin in a cold room (4 ºC). The loaded resin was then washed with 3 column 
volumes of start buffer + 30 mM imidazole and eluted with 3 column volumes of buffer B1 + 
500 mM imidazole. The resulting eluent was desalted using a C4 SPE column (Grace-Vydac) 
following the manufacturer’s instructions. The resulting eluent was lyophilized to dryness. 
Trypsin digestion was performed as above (notebook reference 10Sep2016). 
Biological activity assay of nisin isolated from the periplasmic space. Bacillus subtilis ATCC 
6633 was grown overnight from a single colony in LB broth at 37 °C. A 1:100 dilution of this 
culture was made and the resulting diluted culture grown to an OD600 nm of 0.5. This culture was 
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used to inoculate molten LB by adding 15 L of culture to 15 mL of LB and poured into a plate. 
After the agar had set, 5 L of the periplasmic isolate was spotted at the indicated position. This 
was repeated until a total of 20 L was spotted. A control trypsin reaction containing the same 
buffer and the same amount of trypsin but without peptide added was spotted in the same 
manner. A positive control spot of 3 L of a 0.1 mg/mL nisin solution was also spotted. Spots 
were dried under a flame and the plate was then placed in a 30 °C incubator and imaged after 8 h 
of growth (Notebook references 14Sep2016, 15Sep2016, 16Sep2016).  
To determine approximately how much nisin was present in the periplasmic isolate, the image of 
the bioactivity plate was imported into ImageJ (National Institutes of Health).51 The areas of the 
zone of growth inhibition of a known concentration of nisin and the periplasmic isolate were 
determined. Using the equation below, the approximate concentration of nisin from the spotted 
periplasmic isolate was determined to be 0.05 mg/mL.  
 
The total amount of nisin present in the periplasm in the entire 1.5 L culture was then determined 
to be 0.02 mg: 
 
This corresponds to 6 nmol in a 1.5 L culture. Assuming that nisin production is roughly the 
same in the phage-making cultures, this corresponds to 0.4 nmol of nisin produced in a 100 mL 
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culture. Since the same culture at optimal yield produces 1 mL of 1013 phage virions = 0.02 
nmols phage, there is at least a 20-fold excess of nisin produced and exported to the periplasm.  
Expression and purification of NisP. E. coli BL21(DE3)-T1R was transformed with pRSF-
NisP. An overnight LB culture of the freshly transformed cells was used to make a 1% v/v 
inoculation in LB (500 mL) containing kanamycin (50 g/mL). The culture was grown at 37 °C 
with shaking at 200 rpm to OD600 = 0.6 to 0.8, at which point protein expression was induced 
with IPTG (0.5 mM) and the culture was allowed to grow overnight at 18 °C. The cell pellet was 
harvested by centrifugation at 5,000 × g for 20 min at 4 ºC and stored at -80 ºC (Notebook 
references 13Feb2017, 14Feb2017).  
The frozen cell pellet was thawed and resuspended at 5 mL/g of cell paste in start buffer (20 mM 
HEPES, 500 mM NaCl, 10% glycerol, 5 mM imidazole). The cell pellet was lysed by sonication 
(50% amplitude, 1 s on, 2 s off, 2 min total time) and the insoluble matter was pelleted by 
centrifugation at 14,000 × g  for 25 min at 4 °C. The supernatant was then loaded on 5 mL of Ni-
IDA resin in a cold room (4 ºC). The loaded resin was then washed with 3 column volumes of 
start buffer + 60 mM imidazole and eluted with 3 column volumes of start buffer + 500 mM 
imidazole. The resulting eluent was concentrated by using a 15 mL 10 kDa molecular weight 
cutoff Amicon filter until ~1 mL remained. This retentate was then diluted to 10 times the 
concentrated volume with start buffer and the concentration procedure was repeated two 
additional times to reduce the imidazole concentration. The resulting NisP was then split into 10 




Phage digestion with NisP. To 30 L of phage (~1012 virions/mL) was added 0.3 L of NisP 
(30 g/mL). The reaction mixture was placed at 37 ºC for 1.5 h (notebook reference 
31Aug2017).  
Western blot analysis of phage. Phage samples were prepared by adding 20 L of Ni-IDA 
resin, pre-equilibrated in PBS, followed by mixing and pelleting the resin by centrifugation at 
1000 × g for 5 min to remove any contaminating proteins that may interfere with the HisTag 
antibody. The supernatant containing the phage was removed and combined at a 5:1 ratio with 6x 
Laemmli loading dye followed by boiling at 95 ºC for 5 min. Samples were cooled to room 
temperature then loaded into and resolved on pre-cast 4-20 % gradient polyacrylamide gels. 
Bands were then transferred onto PVDF membranes and incubated with the His-Tag antibody 
and the secondary, HRP-linked antibody as per the manufacturer’s recommendations. The 
substrate was then added and the image developed on X-ray film. A digital image was created 
through photographing the physical copy. The digital photograph was then changed to grayscale 
and the ImageJ software was used for densitometric determinations (notebook reference 
31Aug2017, 06Jul2017, 26Jul2017).  
Construction of the library encoding variants of rings A and B of nisin. The plasmid 
pTSP3H-NisACut was constructed via amplification of the pTSP3H-NisA backbone with 
primers pTSP3H_abringCutF and pTSP3H_abringCutR followed by isothermal assembly to 
yield pTSP3H-NisACut, which inserted the NcoI and HindIII cut sites in the nisA gene in place 
of the A/B rings. The oligonucleotides NisABLib2_f and NisABLib2_r were annealed and used 
as a PCR template with primers NisABringAdd1 and NisABringAdd1comp (Table 3.2). The 
oligonucleotide was purified using a Qiagen PCR cleanup kit. The pTSP3H-NisACut construct 
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was digested with NcoI and HindIII and purified using a Qiagen PCR cleanup kit. 
Approximately 4 g of linearized plasmid and 1 g of PCR-amplified oligonucleotide were 
combined in an isothermal assembly then purified using a Qiagen PCR cleanup kit to yield the 
library of nisA encoding the NNK-randomized A- and B- rings. Electrocompetent E. coli SS320 
cells containing pAT7C-NisBC were transformed with 2.14 g of the constructed library. Serial 
dilutions of the transformation were plated to determine the transformation efficiency and the 
remainder of the transformation was expanded in 200 mL of 2xYT containing 10 g/mL 
tetracycline, 25 g/mL chloramphenicol, and 100 g/mL ampicillin. After overnight incubation 
at 37 °C, 10 mL of this culture was transferred into 200 mL of 2xYT containing 25 g/mL 
chloramphenicol and 100 g/mL ampicillin. Phage bearing modified NisA variants was then 
produced from this culture following the procedure described above for production and 
purification of modified NisA-bearing phage. The final yield of the phage library was 1 mL of 2 
× 1012 virions/mL (notebook reference 19Jun2017, 23Jun2017).  
Synthesis of lipid II. Lipid II was synthesized by Dr. Mark Walker chemoenzymatically 
according to a previously reported protocol.21  
Phage library screening. A 250 L aliquot of the phage was digested with NisP as described 
above.  An aliquot of this solution was diluted to a final concentration of 1 × 1011 virions/mL. 
Then 3.5 L of the biotinylated lipid II solution was dried and resuspended in 35 L of 10% v/v 
Triton X-100 in PBS with sonication, resulting in a 0.3 mM biotin-lipid II solution. The phage 
was divided into six aliquots of 45 L each, and 5 L of biotin-lipid solution was added to three 
of the aliquots. Then 5 L of 10% v/v Triton X-100 was added to the remaining three samples – 
these samples represent the control selection lacking a lipid II binding partner. All samples were 
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kept at 37 °C with shaking for 30 min to allow binding of biotin-lipid II. Then 5 L of streptactin 
resin pre-equilibrated in 1% v/v Triton X-100 was added to each sample and they were kept at 37 
°C with shaking for 20 min. The resin was pelleted by centrifugation at 1000 × g for 3 min, and 
the supernatant was removed. Then 100 L of 1% v/v Triton X-100 in PBS was added to the 
resin, the suspension was mixed well, and the resin was pelleted by centrifugation at 1000 × g for 
3 min. This wash step was repeated an additional two times. The bound phages were eluted by 
adding 25 L of 3.3 M nisin in 1% v/v Triton X-100 and shaking at 37 °C for 20 min. The resin 
was pelleted by centrifugation at 1000 × g for 3 min and removed, and the supernatant 
containing the eluted phage was saved. Then 15 L of each eluent was added to 1 mL of 2xYT 
and 3 mL of E. coli SS320 cells at an OD600 nm = 0.5, and the cells were placed on a shaker at 37 
°C for 45 min. In triplicate, 5 L of the non-selected phage library was added to 1 mL of 2xYT 
and 3 mL of E. coli SS320 at OD600 nm = 0.5, and the cells were placed on a shaker at 37 °C for 
45 min – this sample was used to determine the unselected library diversity. Ampicillin was 
added to each of the cultures to a final concentration of 112 g/mL and the cells were kept in the 
shaker for an additional 7.5 h. Then 3.2 mL of each culture was harvested via centrifugation at 
4200 × g. The plasmid was isolated from each culture using a Qiagen plasmid MiniPrep kit, 
yielding three plasmid pools each for selection with lipid II binding partner, selection without 
lipid II binding partner, and phage library with no selection (notebook reference 30Jun2017). 
Biotinylation of lipid II. A 150 L sample of a 3 mM lipid II solution in chloroform was dried 
under a stream of nitrogen. Five equivalents of EZ link NHS-PEG12-biotin (Thermo-Fisher) 
dissolved in DMSO was added directly to the lipid II. Then 250 L of 2:3:1 
chloroform:methanol:water was added and the solution was mixed well and placed on ice, and 
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the reaction was monitored by TLC (developing solution: 2:3:1:0.5 
chloroform:methanol:water:ammonia). Once TLC indicated the reaction was complete (~9 h), 
the product was purified by loading onto a column of DEAE cellulose in the acetate form pre-
equilibrated with 2:3:1 chloroform:methanol:water. The column was washed with 10 column 
volumes of 2:3:1 chloroform:methanol:water then eluted with 5 column volumes of 2:3:1 
chloroform:methanol:300 mM ammonium bicarbonate. The solvent was removed via rotary 
evaporation, and then the remaining water was removed via lyophilization. To the residue was 
added 1:1 chloroform:methanol to 3 mM concentration and the solution was stored at -20 °C 
(notebook reference 10Apr2017). 
Deep sequencing of the phage library. The isolated plasmids were used as template for PCR 
reactions using primers ABlibseq_f and ABlibseq_r to amplify a region spanning the degenerate 
codons. The reactions were run for 15 cycles then purified using a Qiagen PCR cleanup kit. The 
product was used as template for the adaptor and barcoding PCR with the Illumina Nextera XT 
index kit per the manufacturer’s protocol. The libraries were pooled and run in a single lane of an 
Illumina HiSeq 2500 with 100 bp single end reads at the Roy J. Carver Biotechnology Center 
(UIUC) (notebook reference 26Jun2017).  
Deep sequencing data analysis. An in-house python script for library analysis was developed 
by Dr. Mark Walker. This script was used to process the Illumina reads. The reads were screened 
for the nucleotide sequence ATTACAAGTNNNNNNNNNTGTACANNNNNNTGTAAAACA, 
encoding three residues preceding the degenerate bases, the randomized three residues within the 
A-ring of nisin, the unvaried Cys and Thr residues required for formation of the A- and B-ring of 
nisin, the randomized two residues within the B-ring of nisin, and three residues following the 
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randomized B-ring including the Cys residue required for B-ring cyclization. The quality scores 
for each of these bases were analyzed and if any base had a quality score below 30, the read was 
discarded. The reads were then translated and the number of times a sequence was represented in 
the library was quantified and the proportion of each amino acid at each position was calculated. 
Enrichment was calculated using the following equations: 
 
 
Expression and purification of nisin A-I4F/L6P/P9M/G10L. E. coli SS320 was transformed 
with pRSF-FSPML and pAT7C-NisBC. An overnight culture of the freshly transformed cells 
grown in TB medium containing kanamycin (50 g/mL) and chloramphenicol (25 g/mL) was 
used to make a 1% v/v inoculation in TB (1000 mL) containing kanamycin (50 g/mL) and 
chloramphenicol (25 g/mL). The culture was grown at 37 °C with shaking at 200 rpm to OD600 
= 0.6 to 0.8, at which point protein expression was induced with IPTG (0.2 mM) and arabinose 
(0.04% w/v) and the culture was allowed to grow overnight at 27.5 °C. The cell pellet was 
harvested by centrifugation at 5,000 × g for 20 min at 4 ºC and stored at -80 ºC (notebook 
reference 10Oct2017).  
The frozen cell pellet was thawed and resuspended at 5 mL/g of cell paste in LanA buffer B1 
(defined above). The cell pellet was lysed by sonication (50% amplitude, 1 s on, 2 s off, 6 min 
total time) then the insoluble matter was pelleted by centrifugation at 25,000 × g for 25 min at 4 
°C. The supernatant was then loaded on 5 mL of Ni-IDA resin in a cold room (4 ºC). The loaded 
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resin was then washed with 3 column volumes of start buffer B1 + 60 mM imidazole and eluted 
with 3 column volumes of start buffer + 500 mM imidazole. The resulting eluent was desalted 
using a C4 SPE column (Grace-Vydac) following the manufacturer’s instructions. The resulting 
eluent was lyophilized to dryness. 
 
The lyophilized peptide was resuspended in 3 mL of pure water with sonication. Then 3 mL of 
100 mM sodium citrate (pH 5.2; this pH was chosen to maximize solubility and NisP activity30) 
was added and the solution was mixed well. Some precipitation was observed. To this solution, 3 
L of expressed and purified NisP was added and the reaction was incubated for 2 h at 30 oC, 
after which 1 mL of guanidine-containing buffer (20 mM sodium phosphate, 500 mM sodium 
chloride, 0.5 mM imidazole, and 6 M guanidinium chloride, pH 7.5) was added to solubilize any 
precipitate. The reaction was allowed to continue for 1 h, then one additional mL of guanidine 
buffer was added. The reaction was thoroughly mixed then run through 3 mL of Ni-IDA resin 
pre-equilibrated with guanidine buffer to adhere NisP, the proteolyzed leader peptide, and any 
undigested NisA-I4F/L6P/P9M/G10L. The Ni-IDA column was then washed with 1 mL of 
guanidine buffer. The Ni-IDA flow-through was applied to thiopropyl sepharose 6B (GE Life 
Sciences) pre-equilbrated with guanidine buffer to remove any incompletely cyclized peptide. 
The flow-through was desalted using a C4 SPE column (Grace-Vydac) following the 
manufacturer’s instructions. The resulting eluent was lyophilized to dryness, yielding nisin A-
I4F/L6P/P9M/G10L (Notebook reference 08Jan2018). 
Liquid chromatography-mass spectrometry of nisin A and the variant nisin A-
I4F/L6P/P9M/G10L. Tandem mass spectrometry of the lanthipeptides was performed on a 
Waters Synapt Time-of-Flight mass spectrometer with a Waters Acquity UPLC system. On an 
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Acquity UPLC BEH column (1.7 m, C8, 100 × 1 mm), a linear gradient from 97:3 mobile 
phase A (0.1% formic acid in water):mobile phase B (0.1% formic acid in acetonitrile) to 50:50 
mobile phase A:B over 20 min was used to analyze the peptides (Notebook reference 
21Nov2017).  
N-Ethylmaleimide assay. Core peptides were dissolved at ~ 0.1 mg/mL in water. Then 5 L of 
this solution was combined with 4 L Tris buffer (100 mM, 2 M guanidine hydrochloride, pH 
7.0). To this solution, 0.5 L of 100 mM dithiothreitol was added, followed by 0.5 L of 0.5 M 
N-ethylmaleimide (NEM). Solutions were mixed well and incubated at 37 °C for 15 min. The 
reactions were then desalted by Zip Tip (Millipore) and analyzed via MALDI-TOF MS 
(Notebook reference 14Nov2017).  
Biological activity assay of nisin variant. The nisin variant NisA-I4F/L6P/P9M/G10L was 
dissolved at 2 mg/mL in water resulting in a clear solution. To 30 L of this solution, 30 L of 
sterile sodium citrate buffer at pH 5.2 was added (note that this low pH is believed to maximize 
the amount of solubilized variant), resulting in precipitation of some of the variant. The solution 
was sonicated for 5 min then spun at 23897 × g for 30 s to pellet any undissolved material. An 
overnight culture of Lactococcus lactis NZ9000 was used to inoculate molten M17 agar with 
0.5% w/v glucose by adding 15 L of culture to 15 mL of molten agar. The inoculated agar was 
poured into a plate. After the agar had set, 15 L of the variant was spotted at the indicated 
position. This procedure was repeated a second time for a total of 30 L spotted. A negative 
control of the buffer only was spotted in the same manner. A positive control spot of 5 L of a 
0.1 mg/mL nisin solution was also spotted. Spots were dried and the plate was then placed in a 
30 °C incubator and imaged after 2 days of growth (notebook reference 21Nov2017).  
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Characterization of the lipid II-peptide interaction using 31P NMR spectroscopy. NMR 
experiments were performed on an Agilent 600 MHz instrument with a OneNMR broadband 
probe, and the data was analyzed with MestreNova software. Lyophilized lipid II was dissolved 
in 320 L of perdeuterated dimethyl sulfoxide (Cambridge Isotope Laboratories, Inc.) to yield a 
lipid II solution at approximately 1 mM. The NMR spectrum was acquired. The solution was 
then added to the lyophilized nisin variant NisA-I4F/L6P/P9M/G10L and mixed well to yield a 
solution of approximately 1 mM lipid II and 1 mM variant. The spectrum was then acquired for 
this sample. A fresh solution of 1 mM lipid II with 1 mM nisin A was prepared in a similar 
manner and the spectrum was acquired. As an additional control, a 320 L solution consisting of 
solely the peptide variant NisA-I4F/L6P/P9M/G10L at 1 mM was also prepared and the 
spectrum acquired to verify that no pyrophosphate-containing contaminants were present 
(notebook reference 05Jan2018, 06Jan2018).  
Table 3.1. Predicted and observed fragment ions of modified nisin A and the characterized 





Ion Predicted Observed 
 
Predicted Observed 
b2 197.1285 197.1304 
 
197.1285 197.1312 
b3 266.1499 266.1530 
 
266.1499 266.1533 
b4 379.2340 379.2393 
 
413.2183 413.2089 
b29 2788.2141 2788.1973 
 
2914.2280 2914.2419 
b31 3038.3571 3038.3403 
 
3164.3710 N/A 
y2 216.1343 216.1370 
 
216.1343 216.1376 
y4 452.2616 452.2665  452.2616 452.2661 
y13 1360.6613 1360.6526  1360.6613 1360.6534 
y15 1605.7447 1605.7255  1605.7447 1605.7703 
y22 2220.9956 2220.9783  2220.9956 2221.0415 
y30 2974.3258 2974.2949  3066.3554 3066.3167 
y32 3156.4313 3156.3784  3282.4452 3282.4264 
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Table 3.4. List of plasmids and phagemids used. 
Plasmid WAV 
Inventory 
Marker Insert Site Reference 
pJF3H 00149 Amp N/A N/A  10 
pJF3H-NisA 02188 Amp His6NisA BssHII, NotI  This study 
pRSF-NisA 00363 Kan His6-nisA N/A 
19 
pTSP3H-NisA 02190 Amp sstorA-His6-nisA-pIII N/A This study 
pTSP3H_no_pIII-NisA 02567 Amp sstorA-His6-nisA-His6 N/A This study 
pACYC-NisBCT7  Cam nisB/nisC/t7RNAP N/A This study 
pAT7C-NisBC 02193 Cam nisB/nisC/t7RNAP N/A This study 
pBR33-T7RNAP  Amp t7 RNA polymerase  N/A S. Martinis, UIUC 
pBAD/HisA-T7RNAP 02208 Amp t7 RNA polymerase HindIII, NcoI This study 
pRSF-NisP 02820 Kan nisP (residues 195-651) N/A This study 
pRSF-FSPML 03048 Kan nisA I4F/L6P/P9M/G10L N/A This study 
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CHAPTER 4: UTILITY OF PHAGE DISPLAYING MODIFIED NISA 
4.1 Introduction  
 In 1917, Felix d’Herelle described the first isolation of bacteriophage, terming it an 
“invisible microbe endowed with an antagonistic property.”1 He noted that this invisible microbe 
could be deployed in animals to alleviate bacterial infections.2 He rapidly extended his studies to 
humans, dosing five children suffering from dysentery with a phage solution, all five of whom 
recovered.3 In ensuing decades, d’Herelle expanded his bacteriophage therapy across the globe, 
reporting cures of typhus and plague as well as rapid containment of cholera epidemics.4 
However, d’Herelle’s reports generated significant skepticism, due in part to many phage therapy 
failures caused by a lack of mechanistic understanding around the phage itself – how it acted to 
kill bacteria, how it reproduced and maintained potency, and how narrow or broad a host range it 
infected.4 In light of these concerns, the clinical introduction of penicillin and other antimicrobial 
therapies in the late 1930’s led to the virtual extinction of phage therapy in the West, although its 
use continued in some non-Western countries, notably Poland and the Republic of Georgia.3  
 Bacteriophage therapy languished in the background through the golden age of 
antibiotics; however, as the specter of antibiotic resistance rose in the 1990s so, too, did interest 
in phage therapy. In a 2009 clinical study of phage to treat chronic otitis due to resistant 
Pseudomonas aeruginosa, a phage cocktail met clinical endpoints in the first Western phage trial 
meeting modern clinical norms.5 Unlike the first trials decades earlier, this study benefited from 
the wealth of knowledge about phage biology generated in the years after its initial description. 
Foremost among these advances was the knowledge that phage infection relies on an interaction 
between the phage and a species or even strain-specific receptor protein in the bacteria. Hence, to 
have a chance of being effective, treatment requires either detailed knowledge of the pathogenic 
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species, allowing deployment of an effective phage, or deploying a cocktail of phage that targets 
a broader swath of species.6,7 Even these measures, though, are not completely effective. Phage 
and bacteria have coexisted for millennia, and the two can quickly reach an equilibrium and the 
phage will not effectively clear the infection.6  Additionally, the extraordinary specificity of the 
interaction of the phage and the bacterial receptor means that resistance can rapidly arise because 
slight mutations in the receptor can negate the phage’s ability to bind it and prevent infection.7 
This inherent specificity of the phage-bacteria interaction complicates further development of 
phage therapy. 
 
Aware of these challenges with phage therapy, I wondered whether displaying a broad-
spectrum antimicrobial peptide on the phage as described in chapter 3 of this dissertation had in 
fact created a phage with a broad host range. The phage used in the display, bacteriophage M13, 
natively infects only Escherichia coli that expresses the F pilus. The N-terminal region of the 
protein pIII, used as the fusion partner for phage display,  is required for its infectivity and 
endows the phage with its specificity (Figure 4.1).8 The pIII protein is divided into three 
Figure 4.1. Interaction required for phage M13 to infect its native host, E. coli bearing the F pilus. Note that to 




domains, separated by linker regions, and naturally folds in a compact formation. When infecting 
E. coli, domain N2 first interacts with the tip of the F pilus. Upon this interaction, the F pilus 
retracts, drawing the phage into the periplasmic space. Once in the periplasmic space, the phage 
relies on interactions with the TolA receptor to complete its invasion of the bacterium.  Next, pIII 
unfolds and domain N1 is now free to interact with the TolA receptor, which is embedded in the 
inner membrane. The anchoring of the N1 domains to TolA sets the phage for the final 
interaction required for infection, that of the C domain of pIII with the TolQ and/or TolR 
receptor. This is a helix-helix interaction and is believed to insert the phage into the inner 
membrane. Following this insertion, the capsid proteins embed in the inner membrane, pushing 
the single-stranded phage genome into the cytoplasmic space, and the bacterium is now infected.  
The specificity of phage infection depends on the interaction of the N2 domain with the F 
pilus. Mutations within the N2 domain or to the F pilus result in a non-infective phage.8,9 
Additionally, the crucial interaction for penetrating the inner membrane is the pIII C-domain 
interaction with TolQ/TolR. If the helix segment of the C-domain is mutated, the phage will still 
insert into the periplasmic space and bind TolA through domain N1, but it then stalls and the 
bacterium remains uninfected.8  While the specificity of bacteriophage for a particular receptor 
severely limits the range of hosts a given phage can infect, the TolR and TolQ proteins that are 
essential for the entrance of the DNA into the cytosol are widely conserved. The TolQ family of 
proteins (IPR014163) contains the conserved MotA/TolQ/ExbB proton channel domain 
(IPR002898), which is found throughout bacterial phyla. The TolR protein is likewise part of a 
conserved family (IPR014168) found throughout the bacteria domain. An alignment of selected 
bacteria from a broad swath of distantly related bacteria reveals that the transmembrane helix 
portions are highly conserved (Figure 4.2). Since the portion of the C-domain of phage protein 
102 
 
pIII has been identified to contain a GXXXGXXG motif typical of helix-helix interaction 
domains,18 it has been proposed that the transmembrane helical portions of TolR or TolQ are key 
for the interaction of the C-domain of pIII, which allows entrance of the DNA into the 
cytoplasm. Therefore, it seems that the specificity of the phage is conferred by receptor 
recognition of the N-terminal domains, and the C-domain may be capable of fulfilling its role in 
a wide range of host bacteria.  
 
Figure 4.2. Alignment of transmembrane (TM) regions of proteins from the TolQ family and the TolR family 
among a phylogenetically distant set of bacteria. Note that the InterPro identification number for each protein is 
provided in parentheses. Protein alignment and transmembrane helix region prediction performed by PRALINE.10 




 Given that nisin is a strong binder of lipid II and TolR and TolQ are widely conserved, it 
may be possible to use the affinity of modified NisA for the pyrophosphate moiety of lipid II as a 
replacement for the affinity of the N2 domain for the F pilus, thereby allowing the phage to 
leverage lipid II as a receptor (Figure 4.3). This could allow phage displaying modified NisA to 
infect a wide range of Gram-positive bacteria, and such an approach has a literature precedent: a 
chimeric pIII made through augmentation of the host range of the filamentous fd phage through 
fusion of its pIII protein to a portion of the pIII protein from the Ike phage expanded the 
infectivity of the phage to include bacteria with N-pilus in addition to those producing the native 
receptor for fd phage, the F pilus.11 
 
Figure 4.3. Proposed route of infection of Gram positive bacteria by phage displaying modified NisA. Note that 




4.2.1 Transfection of a plasmid into Gram-positive bacteria 
 To test the hypothesis that the modified NisA-displaying phage can transfect its packaged 
DNA into a Gram-positive bacterium, a plasmid containing both an E. coli origin of replication 
and a Bacillus subtilis-compatible origin of replication and erythromycin resistance marker was 
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packaged in phage bearing the nisin-pIII fusion. The phage was incubated with a culture of B. 
subtilis ATCC 6633, a Bacillus strain reported to have no natural competence and to be difficult 
to transform,12 and the bacteria was then plated on LB agar with erythromycin (Figure 4.4). 
Colonies were observed on the resulting plate and a liquid culture was inoculated for plasmid 
extraction. The extracted plasmid was not present in sufficient amounts for sequencing, so it was 
then used to transform competent E. coli, re-extracted, and sent for sequencing. Sequencing 
results demonstrated that the plasmid was indeed that from the phage. 
 
Figure 4.4. B. subtilis colonies observed on LB agar with erythromycin, growing after introduction of a resistance-
containing plasmid using the modified NisA-displaying phage. 
 
Encouraged by its ability to transfect one difficult-to-transform strain of Gram-positive 
bacteria, we next tested the phage’s ability to infect several Streptomyces species. Streptomyces 
has provided a wealth of clinically relevant natural products over the last 60 years and continues 
to be one of the main sources of natural products with desirable activity.13 However, many 
strains of Streptomyces are notoriously difficult to transform, thereby making genetic 
manipulation challenging. We therefore created a shuttle plasmid that could reproduce in E. coli 
or Streptomyces using an apramycin resistance marker and packaged it in phage bearing 
modified NisA. The transfection of Streptomyces cattleya DSM 46488 was readily achieved via 
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mixing germinated spores with the phage, allowing for 12-16 hours of rescue growth, and finally 
plating on MS agar with apramycin (Figure 4.5). As a control, Streptomyces cattleya was plated 
on the same media without first incubating with phage. Colonies were observed only from the 
bacteria incubated with the phage. Isolation of the plasmid from the S. cattleya, transformation of 
E. coli, and final isolation of the plasmid from E. coli followed by sequencing revealed that the 
replicating plasmid could be recovered. We next sought to transduce the fosfazinomycin-
producing Streptomyces sp. NRRL-149. Prior attempts in our lab to transfer DNA into this 
species through conjugation were unsuccessful; moreover, attempts to induce sporulation were 
also unsuccessful, so any transformation technique would need to achieve penetration of the 
mature peptidoglycan. Incubation of the bacteria with the phage, followed by rescue and plating 
as above, resulted in putative transformants. Once again, plasmid isolation, transformation back 
into E. coli, re-isolation and sequencing demonstrated that the replicating plasmid was indeed 
recovered from the bacteria.  
 
Figure 4.5. S. cattleya colonies observed on MS agar with apramycin. (a) A control plate where bacteria not 
incubated with the phage was plated on selective media. (b) A number of colonies growing on a selective media 
plate where the bacteria were first incubated with modified NisA-displaying phage that contained a Streptomyces-
compatible plasmid that would endow infected bacteria with resistance to apramycin. Growth of a colony in a liquid 




4.2.2 Examination of the lipid II-dependence of transfection 
 Although the increased array of host organisms for the modified phage is remarkable, the 
lack of understanding regarding how the phage effects these transformations was troublesome. 
Moreover, the phage used in the above experiments had not been incubated with NisP and likely 
still contained the leader peptide, and modified NisA has not been shown to bind lipid II. To 
determine whether the transfection is due to the lipid II-binding ability of the phage, I designed 
an experiment leveraging flow cytometry. Phage displaying modified NisA were labeled via the 
exposed amines of the pVIII protein (Figure 4.6). Since there are approximately 2700 copies of 
pVIII per phage particle,14 this procedure yields a brightly labeled phage that should be suitable 
for detection via flow cytometry. As a control, a linear NisA-displaying phage was also labeled. 
A portion of each labeled phage population was then treated with trypsin, intending to remove 
the leader peptide, although it should be noted that the trypsin treatment may also remove the 
NisA-related moiety from the phage since there are Arg/Lys residues in the protein connecting 









Figure 4.6. Labeling of phage with NHS-rhodamine. Note that although multiple labeling events occur for each 
phage, the exact number of labels varies and is not established. 
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Given that the phage demonstrated the ability to transfect B. subtilis ATCC 6633, this 
bacterium was chosen as a target. A culture was grown to exponential phase, and the phage 
preparations above were added to four separate aliquots. If the modified NisA-displaying phage 
binds these bacteria, then a fluorescent population of B. subtilis should be visible via flow 
cytometry. To establish that the binding action is due to lipid II-binding, four additional aliquots 
of each phage type were mixed with a 1000-fold excess of free lipid II then mixed with the B. 
subtilis culture.  If the lipid II-binding is responsible for the infectivity, then this phage 
population should be fully bound to lipid II prior to being added to the bacteria and hence would 
not bind. The fluorescent population would therefore be significantly decreased. Finally, since it 
is unknown how many phage actually bind each bacterium to transfect the plasmid, a separate 
population of the B. subtilis was mixed with a low concentration of hen egg white lysozyme. 
This will begin to digest the peptidoglycan, potentially freeing more lipid II for binding and 
resulting in a stronger signal. Following incubation and washing of the bacteria and phage 
mixtures, flow cytometry was used to assess whether any fluorescent populations were formed 
(Figure 4.7). Although slight differences in the fluorescent populations were observed, the signal 




Figure 4.7. Flow cytometric analysis of B. subtilis mixed with phage under various modified testing conditions. 
Although different degrees of fluorescence are observed, no clear pattern can be established. Note that “mod NisA” 
indicates phage displaying modified NisA, whereas “Lin NisA” indicated phage displaying linear (unmodified) 
NisA. Note that the P1 gate was set to exclude the entire population of a control of an unlabeled B. subtilis culture 
whose results are not pictured here. 
 
4.2.3 Leveraging the phage to create a system to evolve new antimicrobial peptides 
 Although nisin has low biological activity against Gram-negative bacteria, some nisin 
mutants do show activity against E. coli.15 One such mutant has a methionine to lysine mutation 
at the 21st residue of the peptide (NisA_M21K). If the increased host range of the phage is 
dependent on the properties of the displayed peptide, then creating phage that displays the 
NisA_M21K mutant of nisin instead of wild type nisin may be able to infect E. coli that does not 
produce the F pilus. This NisA_M21K phage was produced and incubated with E. coli DH10B, a 
strain which does not produce the F pilus and should be immune to M13 phage infection. 
Following incubation with the phage, the E. coli was plated on selective media. As a control, the 
E. coli was also mixed with phage that contained the same ampicillin resistance gene but 
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displayed the wild type modified NisA. Phage displaying the modified NisA_M21K did transfer 
resistance but the wild type modified NisA phage did not, as demonstrated by the presence of 
colonies in selective media only from the E. coli/NisA_M21K bacteria/phage mix (Figure 4.8). 
That the transfected plasmid was the source of the resistance was later verified through plasmid 
extraction and sequencing.  
 
 
Figure 4.8. Comparison of the ability of phage to transfer a plasmid with ampicillin resistance to a population of E. 
coli DH10B spread on ampicillin-containing LB agar. (a) E. coli mixed with wild type modified NisA-displaying 
phage. (b) E. coli mixed with modified NisA_M21K-displaying phage. Colonies were only observed on the right 
side of the plate, corresponding to E. coli incubated with phage bearing modified NisA_M21K peptide. 
 
Since the nisin variant that was weakly active against E. coli was also able, albeit 
inefficiently, to infect E. coli lacking the F pilus, I reasoned that a nisin variant that was more 
active against E. coli may also allow more efficient infection of E. coli. I designed a selection 
methodology to explore and exploit this principle to develop nisin variants that were active 
against Gram-negative bacteria (Figure 4.9). This selection methodology uses the NisA_M21K 
as the template, then generates variants of this nisin sequence through error-prone PCR, and 
finally produces phage bearing those nisin variants. These phage are mixed with a population of 
E. coli that does not bear the F pilus but does bear the nisin modifying enzymes NisB/C. Those 
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variants that can infect this E. coli will reproduce in the infected bacteria and become more 
numerous, whereas those variants that do not infect the E. coli will not reproduce. The antibiotic 
kanamycin is introduced to this culture to kill any uninfected cells, and then phage or viable cells 
are isolated after the introduction of the antibiotic represent the successful nisin variants. 
Moreover, since the infected E. coli bears the nisin modification machinery, this phage will 
display modified nisin variants and can directly be used to infect a new culture of non-F pilus-
bearing E. coli, allowing a sort of discontinuous phage evolution. 
 
Figure 4.9. Directed evolution of nisin variants leveraging the novel infectivity of modified NisA-bearing phage. 
 
To enable this approach, the plasmid transferred from the phage to the bacteria needed to 
bear both the nisin gene and all the required phage proteins. Therefore, the tat-histag-
nisA_M21K-pIII gene including its promoter was copied out of NisA-pTSP3H and assembled 
into the M13KO7 helper phage genome, thereby creating a helper phage variant that under 
conditions inducing the lac operon also produces NisA-displaying phage. This variant was 
termed “TorPhage-NisA,” indicating a helper phage that exports a display peptide via fusion to a 
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Tor signal sequence. Note that this helper phage maintains the helper phage M13 origin, 
allowing its packaging as single-stranded DNA in phage. Additionally, it can replicate itself 
since a single plasmid contains both the phage genome and the NisA gene, allowing selected 
variants to continue to increase in a growing bacterial culture over time. Coexpression of this 
gene with the NisBC-pAT7C plasmid hence produces modified NisA phage. The gene encoding 
NisA_M21K was then used as the template for the creation of a library of NisA variants using 
error-prone PCR. To achieve a high mutation rate, 45 rounds of error-prone PCR were 
performed, in hopes that the library would contain some functional variants and many 
nonfunctional variants, thereby allowing a rapid enrichment of the functional variants. After 
assembly into the TorPhage construct, a library of ~300 nisin variants was created. While this 
library was clearly too small to sample a significant portion of the available chemical space, it 
was used as a validation library: if the approach enriches a variant, then the overall strategy is 
valid and warrants production of a large library.   
With the small library in hand, two rounds of selection were performed and three 
members of the library were sequenced at each round. Sequenced variants from each round 
showed at least two amino acid substitutions per variant, suggesting that the library was quite 
diverse. Moreover, after two rounds of selection the variants appear to converge on a single 
sequence, although the small number of sequences means this cannot be definitively stated. 
Nonetheless, the selection methodology appeared to converge on a single variant and thus 




Figure 4.10. Sequences from the library, first selection (Sel 1), and second selection (Sel 2) of the directed evolution 
experiment. Note that although few sequences are reported, the mutation rate is high (at least 2 mutations per 
sequence). The “asterisk” indicates a stop codon. 
 
The selection conditions, too, suggested that the pool was converging. The first attempt at 
the first round of selection failed. For this attempt, a culture of the host E coli was grown to 
OD600 = 0.4, the phage library was added and incubated with the culture for 1 hour, and the 
selective antibiotic kanamycin was finally added. The culture was allowed to continue to grow. 
After two days of growth, however, the culture remained clear and no viable E, coli was found. 
Therefore, the first round was repeated. A larger culture of E. coli was grown to OD600 = 0.4, the 
bacteria were concentrated 10-fold through centrifugation, and, following the concentration step, 
the phage library was added and incubated with the culture for 1 hour. The culture media was 
then expanded to the original volume, selective antibiotic was added, and bacterial growth was 
observed. After additional growth, phage were isolated from this culture and used to make a new 
phage library. This phage, following one round of selection, was then used for the next round of 
selection. For the second round of selection, the phage was added to a host bacteria culture at 
OD600nm = 0.4 without the concentration step. In this round, no significant die-off was observed 
after the addition of the antibiotic, indicating that the phage after just a single round of selection 




Figure 4.11. The nisin variant identified via phage-based evoluation. (a) Sequence of the nisin variant. (b) MALDI-
TOF MS analysis after its production in E. coli. Bold/red residues in the sequence represent mutations from the wild 
type nisin sequence. Note that as in wild type nisin, 9 dehydratable residues are present, but 8 dehydrations are the 
major product. Observed m/z of the 8-fold dehydrated species: 3360.6 Da. Expected mass: 3361.5 Da. 
 
To assess whether the nisin variant imparting greater infectivity to the phage was also a 
more potent antibiotic against E. coli, the variant was produced in E. coli without the pIII fusion 
and found to be well-tolerated by the processing enzymes (Figure 4.11). However, bioactivity 
testing again E. coli DH10B indicated that the processed variant was not bioactive. Therefore, to 
determine whether the modified variant was responsible for the observed greater infectivity, 
phage was produced bearing the modified nisin variant or the linear nisin variant. These variant-
displaying phage were mixed with E. coli lacking the F pilus, incubated, and plated on selective 
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media (Figure 4.12a and b). As a control, a portion of the bacteria alone was also plated on the 
selective media (Figure 4.12c). No colonies were observed for the control or in the absence of 
modification; however, 10 colonies were found when the E. coli was treated with phage bearing 
the modified nisin variant, strongly suggesting that the variant indeed imparts greater infectivity 
to the phage (Figure 4.12). To determine whether this variant was unique or whether any 
antimicrobial peptide could impart similar infectivity, a phage bearing the magainin 2 
antibacterial peptide, which is active against Gram negative bacteria such as E. coli, was created. 
This phage was then mixed with an aliquot of E. coli DH10B and plated on selective media. 
Phage bearing either the modified nisin variant or the linear nisin variant were also mixed with 
aliquots from the same E. coli population. Results again were striking: over 100 colonies were 
observed on the plate bearing the bacteria mixed with phage bearing the modified nisin variant 
(Figure 4.12d), whereas the other two phage populations showed 12 or fewer colonies (Figure 
4.12e, g). The control of bacteria alone showed no colonies (Figure 4.12f). 
 
 
Figure 4.12. Comparison of infectivity of various phage types. (a,b,c) Comparison of the infectivity of phage 
displaying (a) the modified nisin variant, (b) the linear nisin variant), or (c) a control of no added phage. (d,e,f,g) 
Comparison of infectivity of phage displaying (d) the modified nisin variant, (e) magainin 2, (f) no phage added, (g) 




4.3 Discussion and outlook 
Although leveraging nisin phage display solely for affinity maturation as described in 
chapter 3 has many unexplored applications, the novel infectivity of nisin-bearing phage could 
be revolutionary. As described above, such phage is more broadly infective than wild type phage 
and can transfect DNA into a wide array of bacteria that are normally impervious to M13 phage. 
This technology opens a host of potential applications. If optimized to achieve greater efficiency, 
this phage could be used to perform genetic manipulations of bacteria that are typically difficult 
or impossible to transform, such as Streptomyces. Such work would significantly ease the 
characterization of natural product biosynthesis pathways. If performing this genetic work using 
conventional techniques such as gene recombination is not successful, it should be possible for 
the phage to carry a plasmid bearing a CRISPR-Cas9 array. If the CRISPR-Cas9 proteins are 
functional in the novel host, this approach will allow gene deletion or mutation via non-
homologous end joining or recombination, respectively.16 
The general infectivity of this phage could also be leveraged in novel clinical 
interventions to treat infections. Phage therapy currently requires either using a phage cocktail 
targeting a broad array of pathogens or knowing the target bacteria and having a phage on-hand 
that can destroy it. With a generally infective phage, however, the identify of the pathogenic 
bacteria need not be known. One could mimic the broad-spectrum small molecule therapies 
currently in use through deploying a generally infective phage that transmits a gene encoding a 
toxin, thereby killing the pathogenic and non-pathogenic organisms. Alternatively, a therapeutic 
strategy could leverage bacteria known to be present in healthy microbiota as antibiotic factories. 
In this strategy, the generally infective phage would encode a gene or biosynthetic gene cluster 
that produces an antimicrobial compound as well as a resistance protein. The oligonucleotide 
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sequence as well as the promoters would be optimized to function best or only with the known, 
healthy bacteria. The phage would then transmit this gene cluster to both the pathogenic and non-
pathogenic bacteria, but due to the specificity of the promoter, only the non-pathogenic bacteria 
would produce the compound. In this scenario, the non-pathogenic bacteria would persist after 
clearance of the pathogenic bacteria, thus reducing the likelihood of secondary infections. 
Although such therapeutic interventions will require a significant investment to develop fully, 
the potential advantage gained in the clinic is tremendous. 
In addition to the potential applications of a phage with a broad range of infectivity, the 
selection system designed above could lead directly to improved antimicrobial compounds or to 
further alteration of the phage host range. Although the test selection performed here did not 
yield a nisin analog with improved function against Gram negative bacteria, it did demonstrate 
the feasibility of performing a selection based on phage infectivity. A larger library coupled with 
deep sequencing methods may yield a variety of nisin analogs for further testing. Moreover, the 
displayed moiety does impact the host range of the phage and hence the host range can be 
refined through selection. For example, to develop a phage with a specificity for a given bacterial 
strain, the nucleotide sequence and promoter of the phage genome would be optimized for that 
bacterium, and several rounds of selection would be performed, yielding a large library of phage 
displaying moieties that bind and lead to infection of that bacterium. In ensuing rounds of 
selection, the bacterial culture would be doped with increasing proportions of bacteria that are 
not desired for the phage to target. These bacteria would act as a sponge for the non-specific 
phage, segregating them away from the desired bacteria. Only those phage that do not bind off-
target would persist through rounds of selection, thereby yielding bacterium-specific phages.  
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Finally, as the techniques detailed in this chapter are matured through further selection 
and display of other moieties, their applications will increase still further. This idea originated 
with nisin due to its ability to bind a small molecule that is broadly present in bacteria. However, 
other RiPPs may prove even better for this type of work. Duramycin, for example, binds 
phosphatidylethanolamine, a phospholipid present in greater quantities than lipid II and hence 
may be a more efficient RiPP to assist in transformation. On the other hand, microcin J25 is a 
RiPP that specifically attacks E. coli via a siderophore receptor, and hence could be an ideal 
evolutionary template for targeting specific Gram negative bacteria via surface-exposed 
receptors. Other possibilities abound, and at least one other group has considered the potential 
the therapeutic potential of a similar approach.17 As our understanding of RiPP biosynthesis 
expands, the number of potential templates for the selection system will also expand yielding an 
ever-increasing array of novel, potent phages. 
 
4.4 Materials and methods 
Commercial materials. All chemicals were purchased from ThermoFisher Scientific 
(Pittsburgh, PA) unless otherwise noted. Luria-Bertani (LB) and Terrific Broth (TB) were 
purchased from Fisher Scientific. Streptactin resin was purchased from IBA Lifesciences 
(Goettingen, Germany). Restriction enzymes and Phusion DNA polymerase were purchased 
from New England Biolabs (Ipswich, MA). Plasmid mini-prep kits were purchased from Qiagen 
(Valencia, CA). Amicon centrifugal concentrators were purchased from Millipore (Billerica, 
MA). DNA oligonucleotides and synthetic DNA gene fragments (gBlocks) were purchased from 
Integrated DNA Technologies (Coralville, IA). Sequences of oligonucleotide primers are 
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provided in Table 4.1, and sequences of gBlocks are given in Table 4.2. Table 4.3 lists all 
plasmids and phagemids used or constructed in this study. 
 
Bacterial strains. Escherichia coli DH10B-T1R was used for plasmid construction, BL21 
(DE3)-T1R was used for heterologous protein production, and SS320 was used for phage 
production. Bacillus subtilis ATCC 6633, Streptomyces cattleya DSM 46488, and Streptomyces 
sp. NRRL-S149 were used for transfection studies.  
 
Construction of TorPhage helper phage plasmid. The gene encoding the fusion protein 
consisting of the Tat signal sequence-Hexahistidine tag-NisA-pIII as well as its promoter region 
was cloned from phagemid pTSP3H-NisA using primers TorAforM13_FP and TorAforM13_RP. 
The M13KO7 helper phage plasmid was used as the backbone and was amplified using primers 
M13forTorA_FP and M13forTorA_RP.  The two fragments were combined using isothermal 
assembly to produce TorPhage-NisA. Note that this construct functions like a helper phage 
construct with the addition that it produces the Tat signal sequence-Hexahistidine tag-NisA-pIII 
protein when the lac operon is induced (notebook references 06Nov2015, 09Nov2015). 
Construction of plasmids to be packaged in modified NisA-displaying phage. The gene 
encoding the F1 origin and erythromycin resistance was cloned out of 
pMUTIN_SpaI_FLAG_F1, provided by L. An, using primers F1Ery_FP and F1Ery_RP. The 
plasmid backbone from pAD43-25 was amplified using primers pAD_FP and pAD_RP. The two 
fragments were assembled with isothermal assembly to yield plasmid pADF1EryR (notebook 
references 15Dec2015, 18Dec2015, 21Dec2015).  
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The apramycin resistance cassette was cloned out of pCRISPOMYCES16 using primers 
pCRISP2_FP and pCRISP2_RP. The backbone from pFD666 was amplified using primers 
pFDnoKan_FP and pFDnoKan_RP. The two fragments were united using a Golden Gate 
assembly by combining 1 µL of T4 ligase buffer (10x), 1 µL of CutSmart buffer (10x), 4.0 µL of 
backbone, 2.5 µL of apramycin resistance cassette, 1 µL of BbsI restriction enzyme (10,000 
units/mL), and 0.5 µL of T4 DNA ligase (400,000 units/mL). The reaction was held for 10 min 
at 37 ºC followed by 10 min at 16 ºC for 20 cycles, then held at 65 ºC for 20 min to heat-
inactivate the enzymes. This reaction yielded the plasmid pFDApra2 (notebook references 
26Jan2016, 29Jan2016).  
Construction of phagemids. The two primers mag2_f and mag2_r were annealed by holding an 
equimolar mix at 98 ºC for 1 min then cooling to 4 ºC for 10 s and repeating 5 times. The 
pTSP3H backbone was amplified using primers ptspmag_bbf and ptspmag_bbr. The two were 
combined in an isothermal assembly to yield plasmid pTSP3H-Mag2 (notebook references 
08Mar2016, 09Mar2016).  
The primers NL1mag_f and NL1mag_r were used to amplify the nisin variant NisA 
I4T/T13P/M21E/K22R from the gblock. The pTSP3H backbone was amplified using primers 
ptspmag_bbf and ptspmag_bbr. The two were combined in an isothermal assembly to yield 
plasmid pTSP3H-NisA_ I4T/T13P/M21E/K22R (notebook references 08Mar2016, 09Mar2016).  
Construction of plasmid encoding the NisA variant I4T/T13P/M21E/K22R. The gene 
encoding the NisA I4T/T13P/M21E/K22R variant was ordered as the oligonucleotide 
gblock_NL1S2 (Table 4.2). The plasmid pRSF was digested with BamHI and NcoI, and the 
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digested plasmid and amplified oligonucleotide were combined in an isothermal assembly to 
yield pRSF-NisA_ I4T/T13P/M21E/K22R (notebook reference 05Oct2016). 
Construction of NisA_M21K plasmid. Plasmid pTSP3H-NisA was amplified using primers 
NisA_M21K_FP and NisA_M21K_FP, which contain a sequence that introduces the M21K 
mutation. The PCR product was circularized using an isothermal assembly mix to yield pTSP3H-
NisA_M21K (notebook reference 06Jul2015). 
Construction of TorPhage-NisA library. Error-prone PCR was used to create a library of 
NisA_M21K variants. Using pTSP3H-NisA_M21K as a template, the reaction contained 42.5 
µL of water, 10 µL of Taq buffer (10x), 11 µL of 50 mM MgCl2, 4 µL of dNTP mix (containing 
25 mM dCTP, 25 mM dTTP, 5 mM dATP, and 5 mM dGTP), 10 µL of primers (10 mM each of 
lib_core1RP and lib_core1FP), 10 µL of template, 1 µL of 50 mM MnCl2, and 3 µL of Taq DNA 
polymerase (5 units/µL concentration). This solution was cycled at 94 ºC for 3 min for the initial 
denaturation. The reaction was then denatured for 45 s at 94 ºC, kept at 51 ºC for 30 s to anneal, 
and heated to 72 ºC for 90 s to polymerize, and these steps were repeated 14 times. The final 
product was then purified on a Qiagen miniprep column. To ensure a high degree of mutation, 
the above procedure was repeated carrying the final product forward as template two additional 
times for a total of 45 rounds of error-prone PCR. This experiment was performed by Sarah 
Ackenhusen (notebook references April 15 2016, 4/18/2016, and 4/22/2016). 
The M13KO7 backbone was amplified in two pieces to improve the PCR amplification 
efficiency. The first piece was amplified using primers piii_viii_FP and piii_viii_RP. The second 
piece was amplified using primers pviii_lead_FP and pviii_lead_RP. These two pieces were 
combined with the error-prone PCR product in a Golden Gate assembly following the procedure 
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outlined above to yield the NisA_M21K library. This library was then used to transform E. coli 
DH10B and the cells were grown in liquid culture, yielding helper phage (purified by the 
procedure below) that encoded the library. Serial dilution of the transformants suggests a library 
size of 300. This experiment was performed by Sarah Ackenhusen (notebook reference 
2/25/2016).  
To construct the library, E. coli SS320 was transformed with pAT7C-NisBC. An overnight 
culture in 2xYT containing 25 g/mL chloramphenicol, 10 g/mL tetracycline, and 2% w/v 
glucose was used to inoculate at 1% v/v an expression culture of 2xYT (100 mL) containing 25 
g/mL chloramphenicol. The culture was grown at 37 °C with shaking at 220 rpm to OD600 = 
0.4. The helper phage library stock (at ~1012 pfu/mL) was then added at a ratio of 1:500 (v:v) 
helper phage:culture media. The culture was returned to the shaker at 37 °C with shaking at 220 
rpm for 1 h to allow phage transfection. The culture was removed from the shaker and 
kanamycin was added to 60 g/mL to remove any uninfected E. coli. At the same time, 
production of Tat-NisA-pIII fusion, T7RNAP, and NisB/C was induced by adding arabinose to 
0.04% w/v and IPTG to 1 mM. The culture was returned to the shaker at 27.5 °C with shaking at 
220 rpm for 24 h to produce phage.  
Following production of phage, the cells were pelleted by centrifugation at 14,000 × g for 15 
min. The supernatant was poured off and subjected to a second round of centrifugation at 14,000 
× g for 15 min to pellet any remaining cellular debris. The resulting supernatant was again 
decanted. A solution of 2.5 M NaCl with 20% w/v PEG8000 was added to the decanted 
supernatant at a ratio of 1:4 (v:v). This sample was mixed well and placed on ice for at least 12 h 
to allow the phage to precipitate. After 12 h on ice, the phage was pelleted by centrifugation at 
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10,500 × g for 10 min. The supernatant was aspirated off and the pellet was resuspended in 2 mL 
of PBS. This sample was then centrifuged at 14,000 × g for 15 min to pellet insoluble debris and 
the supernatant was removed via pipet into a fresh vial. The phage was precipitated a second 
time by adding 2.5 M NaCl with 20% w/v PEG8000 at a ratio of 1:4, mixing well, and placing 
on ice for at least 2 h. The phage was again pelleted by centrifugation at 10,500 × g for 10 min, 
the supernatant was aspirated off, and the phage was resuspended in PBS to yield the final 
library. Sterility of the phage was assured through sterile-filtering through a 0.22 m filter or 
heating for greater than 2 min at 65 °C (notebook reference 26May2016).  
Selection of the TorPhage-NisA_M21K library. A selection was attempted first with the 
following conditions but was ultimately unsuccessful. E. coli DH10B was transformed with 
pAT7C-NisBC. An overnight culture in 2xYT containing 25 g/mL chloramphenicol and and 
2% w/v glucose was used to inoculate at 1% v/v a selection culture of 2xYT (50 mL) containing 
25 g/mL chloramphenicol. This culture was grown to OD600 = 0.4, then the phage library (at 
~1012 pfu/mL) was then added at a ratio of 1:500 (v:v) helper phage:culture media. The culture 
was returned to the shaker at 37 °C with shaking at 220 rpm for 1 h to allow phage transfection. 
The culture was removed from the shaker and kanamycin was added to 60 g/mL to remove any 
uninfected E. coli. At the same time, production of Tat-NisA-pIII fusion, T7RNAP, and NisB/C 
was induced by adding arabinose to 0.04% w/v and IPTG to 1 mM with the intent of making 
phage that was already prepared for another round of selection and displayed the encoded, 
modified nisin variant. The culture was returned to the shaker at 27.5 °C with shaking at 220 rpm 
to produce phage. However, after 48 h, no viable cells were observed (notebook references 
26May2016, 28May2016).  
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Given the failed results discussed above, a new strategy was employed for the first selection. E. 
coli DH10B was transformed with pAT7C-NisBC. An overnight culture in 2xYT containing 25 
g/mL chloramphenicol and 2% w/v glucose was used to inoculate at 1% v/v a selection culture 
of 2xYT (100 mL) containing 25 g/mL chloramphenicol. This culture was grown to OD600 = 
0.4, then the entire culture was subjected to centrifugation at 4400 × g for 5 min.  The pellet was 
resuspended in 10 mL of culture media, and then the phage library (at ~1012 pfu/mL) was added 
at a ratio of 1:500 (v:v) helper phage:culture media. The culture was returned to the shaker at 37 
°C with shaking at 220 rpm for 1 h to allow phage transfection, then 90 mL of fresh media was 
added. Kanamycin was added to 50 g/mL to remove any uninfected E. coli. After 30 min of 
additional growth time, production of Tat-NisA-pIII fusion, T7RNAP, and NisB/C was induced 
by adding arabinose to 0.04% w/v and IPTG to 1 mM with the intent of making phage that was 
already prepared for another round of selection. The culture was returned to the shaker at 27.5 °C 
with shaking at 220 rpm to produce phage. Note that the ideal temperature for phage production 
is 30 °C,18 but given that nisin expressions in E. coli is typically performed at lower 
temperatures,19 I reduced the production temperature slightly in hopes of improving the yield. 
After 1.5 h, 200 g/mL of the culture was plated on an LB agar plate with 25 g/mL kanamycin. 
Colonies from this plate were used to inoculate overnight cultures for plasmid isolation and 
sequencing. After 20 h, the OD600 had decreased to 0.3, so the culture was returned to 37 °C 
recognizing that this increased temperature may limit the phage production (notebook reference 
17Jun2016).  
To perform a second round of selection, an overnight culture of 2xYT containing 25 g/mL 
chloramphenicol and 50 g/mL kanamycin was inoculated at 10:100 from the first selection 
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culture. After 3 hours of growth, the OD600 was 0.6. The temperature was reduced to 27.5 °C and 
production of Tat-NisA-pIII fusion, T7RNAP, and NisB/C was induced by adding arabinose to 
0.04% w/v and IPTG to 1 mM. After 18 h of expression, phage was isolated from the culture. 
The cells were pelleted by centrifugation at 14,000 × g for 15 min. The supernatant was poured 
off and subjected to a second round of centrifugation at 14,000 × g for 15 min to pellet any 
remaining cellular debris. The resulting supernatant was again decanted. A solution of 2.5 M 
NaCl with 20% w/v PEG8000 was added to the decanted supernatant at a ratio of 1:4 (v:v). This 
sample was mixed well and placed on ice for at least 12 h to allow the phage to precipitate. After 
12 h on ice, the phage was pelleted by centrifugation at 10,500 × g for 10 min. The supernatant 
was aspirated off and suspended in sufficient PBS to yield a concentration of ~1012 virions/mL 
(notebook references 21Jun2016, 22Jun2016). 
For the second round of selection, E. coli DH10B was transformed with pAT7C-NisBC. An 
overnight culture in 2xYT containing 25 g/mL chloramphenicol and 2% w/v glucose was used 
to inoculate at 1% v/v a selection culture of 2xYT (50 mL) containing 25 g/mL 
chloramphenicol. This culture was grown to OD600 = 0.4, then the phage library (at ~10
12 
pfu/mL) was added at a ratio of 1:500 (v:v) helper phage:culture media. The culture was returned 
to the shaker at 37 °C with shaking at 220 rpm for 1 h to allow phage transfection. The culture 
was removed from the shaker and kanamycin was added to 60 g/mL to remove any uninfected 
E. coli. At the same time, production of Tat-NisA-pIII fusion, T7RNAP, and NisB/C was 
induced by adding arabinose to 0.04% w/v and IPTG to 1 mM with the intent of making phage 
that was already prepared for another round of selection. The culture was returned to the shaker 
at 27.5 °C with shaking at 220 rpm to produce phage. An aliquot was plated on selective media 
to grow colonies to use for sequencing (notebook references 30Jun2016, 01Jul2016). 
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Expression and purification of modified NisA-displaying phage. E. coli SS320 was 
transformed with pTSP3H-NisA and pAT7C-NisBC. An overnight culture in 2xYT containing 
25 g/mL chloramphenicol, 100 g/mL ampicillin, 10 g/mL tetracycline, and 2% w/v glucose 
was used to inoculate at 1% v/v an expression culture of 2xYT (100 mL) containing 25 g/mL 
chloramphenicol and 100 g/mL ampicillin. Note that the tetracycline in the overnight culture 
ensures the F` episome will persist; it is not included in the expression culture because those 
bacteria that lose the F` episome in the expression culture will not be infected by the phage and 
will be killed when kanamycin is added after phage incubation (kanamycin is the antibiotic 
marker for the M13KO7 helper phage). The cultures were grown at 37 °C with shaking at 220 
rpm to OD600 = 0.4. Helper phage M13KO7 stock (at ~10
12 pfu/mL) was then added at a ratio of 
1:500 (v:v) helper phage:culture media. The culture was returned to the shaker at 37 °C with 
shaking at 220 rpm for 1 h to allow phage transfection. The culture was removed from the shaker 
and kanamycin was added to 60 g/mL to remove any uninfected E. coli. At the same time, 
production of Tat-NisA-pIII fusion, T7RNAP, and NisB/C was induced by adding arabinose to 
0.04% w/v and IPTG to 1 mM. The culture was returned to the shaker at 27.5 °C with shaking at 
220 rpm for 24 h to produce phage.  
Following production of phage, the cells were pelleted by centrifugation at 14,000 × g for 15 
min. The supernatant was poured off and subjected to a second round of centrifugation at 14,000 
× g for 15 min to pellet any remaining cellular debris. The resulting supernatant was again 
decanted. A solution of 2.5 M NaCl with 20% w/v PEG8000 was added to the decanted 
supernatant at a ratio of 1:4 (v:v). This sample was mixed well and placed on ice for at least 12 h 
to allow the phage to precipitate. After 12 h on ice, the phage was pelleted by centrifugation at 
10,500 × g for 10 min. The supernatant was aspirated off and the pellet was resuspended in 2 mL 
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of PBS. This sample was then centrifuged at 14,000 × g for 15 min to pellet insoluble debris and 
the supernatant was removed via pipet into a fresh vial. The phage was precipitated a second 
time by adding 2.5 M NaCl with 20% w/v PEG8000 at a ratio of 1:4, mixing well, and placing 
on ice for at least 2 h. The phage was again pelleted by centrifugation at 10,500 × g for 10 min, 
the supernatant was aspirated off, and the phage was resuspended in 500 mL of PBS. The 
concentration of the phage was then determined by UV as previously reported:20  
 
Sterility of the phage was assured through sterile-filtering through a 0.22 m filter.  
Expression and purification of phage for phage-assisted transformation. E. coli SS320 was 
transformed with the plasmid to be packaged in the phage (either pFDApra2 or pADF1EryR) and 
pAT7C-NisBC. An overnight culture in 2xYT containing 25 g/mL chloramphenicol, 50 g/mL 
apramycin (for pFDApra2) or 100 g/mL ampicillin (for pADF1EryR), 10 g/mL tetracycline, 
and 2% w/v glucose was used to inoculate at 1% v/v an expression culture of 2xYT (100 mL) 
containing 25 g/mL chloramphenicol and 50 g/mL apramycin (for pFDApra2) or 100 g/mL 
ampicillin (for pADF1EryR). The cultures were grown at 37 °C with shaking at 220 rpm to 
OD600 = 0.4. TorPhage-NisA stock (at ~10
12 pfu/mL) was then added at a ratio of 1:500 (v:v) 
helper phage:culture media. The culture was returned to the shaker at 37 °C with shaking at 220 
rpm for 1 h to allow phage transfection. The culture was removed from the shaker and 
kanamycin was added to 60 g/mL to remove any uninfected E. coli. At the same time, 
production of Tat-NisA-pIII fusion, T7RNAP, and NisB/C was induced by adding arabinose to 
0.04% w/v and IPTG to 1 mM. The culture was returned to the shaker at 27.5 °C with shaking at 
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220 rpm for ~24 h to produce phage. Purification of the phage was performed following the 
procedure outline above for the production of modified NisA-displaying phage (notebook 
reference 19Jan2016, 21May2016, 29Nov2016). 
Expression and purification of linear NisA-displaying phage. The procedure exactly matched 
that above for production of modified NisA-displaying phage except that E. coli was not co-
transformed with pAT7C-NisBC. Consequently, chloramphenicol was also omitted from the 
culture solutions (notebook references 21Mar2016, 22Mar2016, 23Mar2016).  
Expression and purification of magainin 2-displaying phage. The procedure matched that for 
production of linear NisA-displaying phage except that pTSP3H-Mag2 was used as the 
phagemid vector (notebook references 21Mar2016, 22Mar2016, 23Mar2016). 
Determination of relative infectivity of peptide-displaying phages. A culture of E. coli 
DH10B was grown to an OD600 between 0.3 and 0.5. This culture was divided into aliquots of 
440 L. The concentration of the phages being assessed was determined by UV, and each phage 
solution was diluted with Tris-buffered saline (TBS) to yield 60 L of each phage at ~1012 
virions/mL. The 60 L phage aliquots were combined with the 440 L culture aliquots and 
placed at 37 °C with shaking for 1 h 15 min. After this incubation, the cultures were centrifuged 
at 4400 × g for 4 min and the supernatant was removed. Each pellet was resuspended in 30 L of 
2xYT then spread on individual LB agar with 50 g/mL kanamycin. Plates were placed at 37 °C 
and monitored for growth (notebook reference 03Oct2016).  
Expression and purification of nisin I4T/T13P/M21E/K22R. E. coli BL21 (DE3) was 
transformed with pRSF-NisA_ I4T/T13P/M21E/K22R and pAT7C-NisBC. An overnight culture 
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of the freshly transformed cells grown in LB medium containing kanamycin (50 g/mL) and 
chloramphenicol (25 g/mL) was used to make a 1% v/v inoculation in LB (750 mL) containing 
kanamycin (50 g/mL) and chloramphenicol (25 g/mL). The culture was grown at 37 °C with 
shaking at 200 rpm to OD600 = 1.0, at which point protein expression was induced with IPTG (1 
mM) and the culture was allowed to grow overnight at 18 °C. The cell pellet was harvested by 
centrifugation at 5,000 × g for 20 min at 4 ºC and stored at -80 ºC (notebook reference 
21Oct2016).  
The frozen cell pellet was thawed and resuspended at 5 mL/g of cell paste in LanA buffer B1 (20 
mM sodium phosphate, 500 mM sodium chloride, 0.5 mM imidazole, and 6 M guanidinium 
chloride, pH 7.5). The cell pellet was lysed by repeated freeze-thaw cycles and then the insoluble 
matter was pelleted by centrifugation at 25,000 × g for 25 min at 4 °C. The supernatant was then 
loaded on 5 mL of Ni-IDA resin. The loaded resin was washed with 3 column volumes of buffer 
B1 + 60 mM imidazole and eluted with 3 column volumes of buffer B1 + 500 mM imidazole. 
The resulting eluent was desalted using a C4 SPE column (Grace-Vydac) following the 
manufacturer’s instructions. The resulting eluent was lyophilized to dryness (notebook reference 
24Oct2016). 
 
The lyophilized peptide was resuspended at 2 mg/mL in pure water. To 80 L of this solution, 10  
L of 200 mM Tris-Cl (pH 7.5)/20 mM CaCl2 and 20 L of 0.1 mg/mL trypsin was added. The 
digestion reaction was placed at 37 °C for 45 min. A portion of this reaction was desalted via 
zip-tip and analyzed by MALDI-TOF MS. The remainder was used for bioactivity testing 
(notebook reference 24Oct2016). 
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Bioactivity testing of nisin I4T/T13P/M21E/K22R. A culture of E. coli DH10B was grown to 
mid-log phase. To 10 mL of molten LB agar, 2 L of E. coli were added. The agar was mixed 
well, poured into a plate, and dried under flame. Separate spots were made of 10 L each of the 
digested nisin variant, the undigested nisin variant, and an authentic solution of wild-type nisin. 
As a positive control, 3 L of 50 g/mL kanamycin was spotted. The plate was monitored for 
more than 48 h; however, no zone of inhibition was observed at any time point for either nisin or 
the nisin variant (notebook reference 24Oct2016).  
Labeling of phage with NHS-rhodamine. To 25 L of DMSO, 250 g of NHS-rhodamine was 
added and dissolved. The concentration of the phage population to be labeled was determined as 
described above and adjusted through dilution with PBS to achieve a concentration of ~1012 
virions/mL. To a 100 L aliquot of phage, a ~10-fold excess of rhodamine was added. The 
solution was placed in the dark at room temperature for 1 hour. The phage was precipitated by 
adding 25 L of 2.5 M NaCl with 20% w/v PEG8000, mixing well, and placing on a centrifuge 
at 10500 × g for 10 min. The supernatant was removed. This wash was performed three 
additional times to yield the labeled phage (notebook reference 12Dec2016).  
Flow cytometry analysis of phage binding to B. subtilis ATCC 6633. An 8 mL culture of B. 
subtilis ATCC 6633 in 2xYT was grown to OD600 = 0.4. The culture was pelleted through 
centrifugation at 4000 × g for 5 min and the resultant pellet was resuspended in 2 mL of 2xYT. 
The culture was divided into 100 L aliquots, and the labeled phage were added to the separate 
aliquots to a concentration of ~3 nM. Phage types used were modified NisA phage, modified 
NisA phage combined with 0.01 mg/mL trypsin, linear NisA phage, and linear NisA phage 
combined with 0.01 mg/mL trypsin. An additional set of phage and bacteria aliquots was 
130 
 
prepared in the same manner, and to this second set 0.5 L of an 80 mg/mL hen egg white 
lysozyme solution was added. A third set of phage and bacteria aliquots was prepared in a 
similar manner, except that each phage type was combined with 1.5 L of 2 M lipid II prior to 
being added to the bacteria. A single sample of B. subtilis with no added phage was also 
prepared. All samples were incubated with shaking at 37 °C for 1 h then pelleted through 
centrifugation at 4500 × g for 5 min. The bacterial pellet was washed by resuspending in 1 mL 
PBS, and pelleting again through centrifugation at 4500 × g for 5 min. The pellet was maintained 
on ice until immediately prior to analysis. For analysis, each pellet was resuspended in 400 L of 
PBS then analyzed on a BD LSRII flow cytometry analyzer (notebook reference 13Dec2016). 
Phage-assisted transformation of B. subtilis ATCC 6633. A 5 mL culture of B. subtilis ATCC 
6633 was grown to OD600 = 0.4. The culture was pelleted via centrifugation at 4500 × g for 5 
min. All but 400 L was aspirated away. The pellet was resuspended in the remaining 400 L of 
supernatant, then 50 L of phage packaging the pADF1EryR plasmid was added to the culture. 
The culture was grown for 45 min at 37 °C, then the culture was pelleted via centrifugation at 
4500 × g for 5 min. The supernatant was removed except for 40 L, which was used to 
resuspend the pellet. The resuspended pellet was spread on an LB agar plate containing 0.3 
g/mL erythromycin. The plate was placed at 30 °C and monitored over four days (notebook 
reference 29Jan2016). 
 
A culture of the phage-transformed B. subtilis was inoculated from a single colony in LB agar 
with 0.3 g/mL erythromycin. The plasmid was isolated from this colony via the Qiagen 
sequencing protocol. The plasmid was present in the DNA isolate at low concentration and 
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sequencing was unsuccessful. Therefore, the plasmid isolate was used to transform competent E. 
coli DH10B and re-isolated prior to sequencing (notebook reference 01Feb2016).  
 
Phage-assisted transformation of S. cattleya DSM 46488. A 4.5 mL culture of S. cattleya 
DSM 46488 was started from spores and grown overnight at 28 °C. After ~12 h of growth, two 
aliquots of 1.5 mL were made. To one aliquot, 50 L of phage displaying modified NisA and 
packaging plasmid pFDApra2 was added. To the other, nothing was added. Both were placed on 
a shaker at 28 °C. After 9 h of growth, the cultures were placed on a centrifuge at 4500 × g for 5 
min and 1 mL of supernatant was removed from each tube. The pellet from each tube was 
resuspended in the remaining supernatant and spread on an individual MS agar plate containing 
50 g/mL apramycin. Plates were placed on 30 °C and monitored over 2 weeks (notebook 
reference 12Feb2016).  
 
For plasmid isolation, a 2.5 mL culture of GYM media with 25 g/mL apramycin was inoculated 
with a single colony from the plate. The culture was grown for one week, then pelleted at 4500 × 
g for 5 min. The supernatant was aspirated off and the pellet resuspended in 250 L of Qiagen 
buffer P1. To this suspension, 15 L of hen egg-white lysozyme stock (80 mg/mL) was added 
and the culture was placed at 37 °C for 30 min, then 250 L of Qiagen buffer P2 was added and 
the culture was mixed by inversion. Next, 350 L of Qiagen buffer N3 was added and the tube 
was again mixed by inversion. The tube was next centrifuged at 23000 × g for 5 min. The 
supernatant was loaded on a Qiagen DNA extraction column and the plasmid isolated following 
the typical Qiagen procedure. The plasmid was present in the DNA isolate at low concentration 
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and sequencing was unsuccessful. Therefore, the plasmid isolate was used to transform 
competent E. coli DH10B and re-isolated prior to sequencing (notebook reference 22Mar2016).  
 




























































Table 4.3. List of plasmids and phagemids used. 
Plasmid WAV 
Inventory 
Marker Insert Site Reference 
pTSP3H-NisA 02190 Amp sstorA-His6-nisA-pIII N/A This study 
TorPhage-NisA 02191 Kan sstorA-His6-nisA-pIII N/A This study 
pCRISPOMYCES 03187 Apr N/A N/A H. Zhao, UIUC 
pAD43-25 02204 Cam/Amp N/A N/A Bacillus Genetic Stock 
Center 
pADF1EryR 02205 Amp/Ery F1 ori; apramycin 
resistance 
N/A This study 
pMUTIN_SpaI_FLAG_F1 02420 Amp/Ery N/A N/A L. An, UIUC 
pFD666 02206 Kan N/A N/A W.W. Metcalf, UIUC 
pFDApra2 02207 Apr Apramycin resistance N/A This study 
pTSP3H-NisA 
I4T/T13P/M21E/K22R 
02568 Amp nisA 
I4T/T13P/M21E/K22R 
N/A This study 
pTSP3H-Mag2 03165 Amp Magainin 2 N/A This study 
pRSF-NisA 
I4T/T13P/M21E/K22R 
02569 Amp nisA 
I4T/T13P/M21E/K22R 
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